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Abstract 
 
An effective vaccine to protect against HIV-1/AIDS remains elusive due to the extensive 
mechanisms employed by the HIV-1 virus to evade immune attack. Highly potent 
broadly neutralizing antibodies isolated from chronically infected individuals, however, 
show that such relevant antibodies can be naturally produced, implying that their 
elicitation through vaccination is a realistic possibility. These broadly neutralizing 
antibodies target different regions on the trimeric spikes formed by three protomers of the 
envelope (Env) protein. Each Env protein is comprised of the gp120 surface subunit in 
non-covalent association with the gp41 transmembrane subunit. Four regions have been 
identified: the CD4 binding site, the V1/V2 segment and the V3/glycan area all on the 
gp120 subunit as well as the MPER segment on the gp41 subunit. This dissertation 
focuses on the gp41 MPER segment given its highly conserved amino acid sequence 
among all HIV-1 clades and viral strain isolates and essential function in Env-mediated 
fusion and HIV entry. Of note, the MPER segment contains several adjacent epitopes 
targeted by broadly neutralizing antibodies, suggesting that the immune system is capable 
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of producing neutralizing antibodies against this specific region. Analysis of both clade B 
and C MPER segments shows them to be L-shaped, consisting of two α helices separated 
by a hinge. We have found that the hinge region of the MPER segment provides the 
conformational flexibility necessary for the Env-mediated hemifusion and fusion 
processes.  A significant reduction in virus infectivity is observed when the hinge region 
is disrupted by introduction of two amino acid mutations that eliminate α-helical capping 
residues and the tandem hinge joints. The importance of the hinge region of the MPER 
segment is further supported by the action of four MPER-specific neutralizing antibodies 
2F5, 4E10, 10E8 and Z13E1. These neutralizing antibodies block virus infection by 
disrupting MPER hinge-related function. 
 
To investigate the nature of the humoral immune response in Balb/c mice directed toward 
the MPER, we presented the MPER segment arrayed on liposomes as immunogens to 
mimic its natural viral membrane context. We characterized the elicited antibody 
responses in sera and at the single cell level by combining a novel high-throughput 
microengraving screening system in conjunction with single cell PCR methods, DNA 
sequencing and monoclonal antibody expression rescue. Our results show that a variety 
of Vh and Vk genes are generated with MPER specificity among antibody-secreting bone 
marrow plasma cells. These antibodies demonstrate considerable somatic hypermutation 
and CDRH3 length variability after three immunizations. Collectively, tools are in place 
to investigate the B cell and plasma cell antibody repertoires elicited by such 
MPER/liposome vaccinations and how these can be altered by variation in immunogen 
design. 
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Chapter 1: Introduction 
  
 
 
 HIV/AIDS pandemic 
The Acquired Immune Deficiency Syndrome (AIDS) was first recognized in 1981 among 
young gay men who were inflicted with unusual opportunistic infections and rare 
malignancies (1). Two years later the causative agent of AIDS was identified as a 
retrovirus, termed human immunodeficiency virus (HIV) (2, 3).  In spite of intense effort 
toward HIV prevention and AIDS treatment, HIV/AIDS evolve to become one of the 
most devastating infectious pandemics (4, 5). It was estimated that 34.0 million people 
were living with HIV worldwide at the end of 2011. Although the global number of new 
infections continues to decline, the number of newly infected people is still increasing in 
some areas of the world. For example, the Middle East and North Africa have seen more 
than 35% increases since 2001 (6). There is also evidence suggesting that the incidence 
of HIV infection in Eastern Europe and Central Asia began increasing in the late 2000s 
after being stabilized for several years (6).  
 
HIV classification and distribution 
There are two types of HIV, termed HIV-1 and HIV-2, with slightly different genome 
structures but distinctive antigenic properties (7). HIV-2 has remained confined mainly in 
West Africa, with its highest prevalence rates reported in Guinea-Bissau and Senegal. 
Moreover, most West African countries have experienced a gradual decline in HIV-2 
prevalence and a corresponding increase in HIV-1 infection (8, 9). On the other hand, 
HIV-1 has been spreading rapidly and is responsible for the global pandemic. Based on 
phylogenetic analysis, HIV-1 has been classified into four different groups, each of which 
2 
 
 represents an independent cross-species transmission event (10-12).  Most HIV-1 
infections globally are caused by group M viruses.  Group O was isolated from two 
persons of west-central African origin in 1990 (13) and accounts for less than 1% of 
HIV-1 infections worldwide with distribution restricted in Cameroon and neighboring 
countries as well as in west and south-east Africa. The prototype strain of group N was 
identified in 1998 from a Cameroonian AIDS patient (12) and so far, only 13 cases of 
group N infections have been reported. Group P infections are even rarer with only two 
cases recorded.  
 
Group M viruses have been further categorized into nine subtypes, termed A-D, F-H, J 
and K (14). Additionally, more than 40 different circulating recombinant forms (CRF) 
have been generated when several subtypes are circulating in the population at the same 
time (15). Subtype C was responsible for half of all infections globally in 2004. The 
subtypes A, B, D and G caused 12, 10, 3 and 6% of infections, respectively and the 
subtypes F, H, J and K together contributed to 0.94% of infections. Sub-Saharan Africa 
accommodated 64% of all HIV-1 infections worldwide, among which, 56% are caused by 
subtype C. Subtype C also dominated in India, accounting for 97% of HIV-1 infections in 
India (16). In North America and Western Europe, the major circulating subtype is B. In 
South and South-east Asia (excluding India), the most prevalent HIV-1 is CRF01_AE 
(16). The predominance of different HIV-1 subtypes in distinctive geographic areas 
probably results from a number of population bottlenecks-founder events, in which the 
size of the virus population reduced dramatically (population bottlenecks) and only a 
limited number of surviving viruses (founder) established the new population (10). For 
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 example, the predominant HIV-1 subtype B HIV infections in the United States were 
established by a single migration of the virus from Haiti (17). 
 
HIV transmission 
The transmission of HIV is mediated by HIV-containing body fluids through sexual 
contact across mucosal surfaces, by direct injection with HIV-contaminated drugs, 
needles, syringes, blood or blood products, or by mother-to-infant exposure. Despite the 
low transmission probability of 1 in 1000 heterosexual exposures, heterosexual 
transmission contributes to nearly 70% of HIV-1 infections worldwide with the 
remainder largely attributable to men who have sex with men (MSM), maternal exposure, 
or sharing needles when injecting drugs (18).   
 
HIV Pathogenesis 
Immediately after the first reports of HIV infection, weakened host defenses against 
invading pathogens were reckoned as being responsible for the rare opportunistic 
infections in patients with AIDS (19). Significant loss of CD4+ T cells was recognized 
with CD4+ T cell count becoming one of the key measures for assessing AIDS disease 
progression (20, 21). Once the absolute CD4+ T-cell count falls below a threshold of 200 
T cells per mm3 in the peripheral blood, an individual becomes susceptible to 
characteristic AIDS-defining opportunistic infections and malignancies. Several 
mechanisms have been proposed to account for severe CD4+ T cell depletion. The first 
intuitive explanation is that virus directly kills infected cells. However, Finkel et al. 
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 demonstrated that cell death occurs predominantly in bystander cells rather than in the 
productively infected cells themselves (22).  Also, viral proteins like Env, Vpr, Vpu and 
nef can exploit apoptosis machinery to their own advantages (23). Surprisingly, profound 
CD4+ T cell depletion (CD4+ T cell counts less than 50 per cm3 for over ﬁve years) did 
not induce AIDS in experimentally SIV-infected sooty mangabeys (24, 25).  The 
comparative studies on nonpathogenic SIV infection of sooty mangabeys and pathogenic 
infections of rhesus macaques support the idea that chronic immune activation plays a 
major role in HIV/SIV pathogenesis (26, 27). 
 
Several factors might contribute to the chronic, generalized immune activation observed 
during pathogenic HIV or SIV infection. The first is the direct effect of HIV, which can 
activate innate immune receptors Toll-like receptor 7/8 and induce strong MyD88-
dependent plasmacytoid dendritic cell and monocyte activation, as well as accessory cell-
dependent T cell activation (28).  Accordingly, following administration of highly active 
antiretroviral drugs, the reduction in immune activation is closely associated with the 
decrease of HIV-1 viremia (29, 30). Another factor that has been implicated in chronic 
immune activation is the host immune response against HIV through TCR recognition of 
peptides derived from HIV-1 or accompanying pathogens (31). Proinflammatory 
cytokines such as TNF-α, IL-1, IL-12, IL-6 and IFN-α are also involved in HIV-induced 
generalized immune activation. These proinflammatory cytokines are produced during 
the acute phase of HIV-1 infection and some are maintained at elevated levels during the 
chronic phase (32). Recently, early damage to the mucosal CD4+ T cell defense and 
subsequently increased translocation of microbial products across the mucosal barrier has 
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 been recognized as a major contribution to the systemic immune activation. 
Lipopolysaccharide (LPS), a component of the cell wall of gram-negative bacteria and an 
agonist of Toll-like receptor 4 (TLR4), is considered a reliable marker of microbial 
translocation (33, 34). In patients with HIV infection, plasma LPS levels increased 
compared to patients without HIV infection. Also, after initiation of highly active 
antiretroviral therapy, LPS level decreased along with attenuated immune activation. 
These findings suggest that microbial translocation causes systemic immune activation in 
chronic HIV infection (33).  
 
HIV structure and genomic organization 
HIV is about 120 nanometer (nm) in diameter and roughly spherical in shape (35). It is 
enveloped with a double-layer membrane derived from the membrane of host cells in the 
budding process. Not surprisingly, therefore, a variety of host proteins can be found on 
the envelope of virions generated from HIV-1 infected cells (36). The single virus-
derived protein carried on the envelope of the infectious virion is gp160. gp160 forms a 
trimer of non-covalent heterodimers of surface protein (gp120) and transmembrane 
protein (gp41) (Figure 1.1). Beneath the inner leaflet of the viral envelope is a 
myristoylated polypeptide matrix (MA), forming a protective shell.  The viral core is a 
cone-shaped capsid (CA), made up of about 5000 copies of viral protein p24 per virion. 
Two copies of single-strand RNA genome, approximately 9.7 kilobases in length, 
together with nucleocapsid (NC) proteins, reverse transcriptase and integrase are 
enclosed within the capsid (Figure 1.1).  
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Figure 1.1. Organization of HIV-1 virions. The left panel (Credit: NIAID) shows all the major 
components of HIV virions. The right panel shows the 3D structure of Env trimer in blue on the 
native HIV-1 membrane as defined by cryoelectron tomography (35). 
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 There are 9 genes contained in the HIV genome, including three genes encoding 
structural proteins (Gag, Pol, and Env), 2 genes encoding regulatory proteins (Tat, Rev), 
and 4 genes encoding accessory proteins (Nef, Vpr, Vpu, and Vif) (Figure 1.2).  
 
Gag protein is synthesized as a 55-kilodalton precursor polypeptide, also called p55, 
which is cleaved by the virally encoded protease into 4 proteins: MA (p17), CA (p24), 
NC (p9) and p6 in the mature virion. MA targets Gag precursor to the plasma membrane 
for virion assembly and also promotes Env incorporation into the newly formed virions 
(37). The N-terminal region of MA also contains nuclear localization signal, which can 
guide the preintegration complex (PIC) through the nuclear membrane of non-dividing 
cells (38, 39).  
 
The HIV-1 pol gene encodes three viral enzymes: these are reverse transcriptase, protease, 
and integrase. They are initially synthesized in the context of Gag-Pol fusion protein 
resulting from a ribosomal shifting event due to a stem-loop structure downstream of the 
frame shift site (40). This mechanism ensures that pol-encoded gene products are 
assembled into newly formed virions by virtue of nuclear localization signals contained 
in Gag protein. Also, the frequency of ribosomal shifting determines the ratio of Gag 
proteins to Gag-Pol fusion proteins, allowing the efficient assembly of infectious virions 
(41). Catalyzed by viral enzyme protease, Gag protein is cleaved off from Gag-Pol fusion 
protein. Subsequent processing of Pol polypeptide yields three enzymes: protease (p10), 
reverse transcriptase (RT, p66), and integrase (IN, p31). All of these enzymes are 
essential for viral infectivity. Protease activity is required for the processing of Gag and  
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Figure 1.2. Genetic organization of HIV-1 (Adapted from Swanson CM and Malim MH, 
2008(42)). The HIV-1 RNA genome is composed of two LTRs (long terminal repeats) at both 
ends and structural genes (dark gray) and accessory/regulatory genes (various colors). TAR 
(Trans-activating response element) is bound by Tat to promote viral transcription. PBS (primer-
binding site for tRNALys3) Initiates reverse transcription. ψ, RNA packaging signal. RRE is bound 
by Rev protein to export unspliced viral RNAs 
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 Gag-Pol precursors into its active components. RT can be divided into three domains, the 
N-terminal polymerase domain, the C-terminal RNase H domain and an intervening 
linker domain. The polymerase domain contains both RNA-dependent as well as DNA-
dependent polymerase activity and it catalyzes the synthesis of double-strand 
complementary DNA from the single-strand RNA genome. The RNase H domain can 
remove the RNA template by non-specifically degrading the (+) strand RNA genome, 
and also specifically removes the polypurine tract primer for (+) strand DNA synthesis 
and the tRNA primer for (-) strand DNA synthesis (43). Due to lack of proofreading 
exonuclease activity, HIV-1 RT is an error-prone polymerase and the HIV-1 mutation 
rate has been reported at 5.9 × 10-4–5.3 × 10-5 mutations/base pair/cycle in vitro (44). 
Integrase mediates the insertion of proviral DNA into the genomic DNA of the infected 
cell (45).  
 
Envelope protein (Env, gp160) is the surface protein that is embedded in the viral 
membrane and mediates the fusion of viral membrane with the membrane from the target 
cell. It is synthesized from bicistronic vpu/env mRNA on rough endoplasmic reticulum 
(RER) as a precursor of about 850 amino acids in length and forms predominantly trimers 
(46, 47). In the Golgi, gp160 is cleaved by cellular furin or furin-like proteases to 
generate the surface gp120 and transmembrane gp41 subunits. gp120 binds cell surface 
receptor CD4 and its coreceptor CXCR4 or CCR5 to mediate virus attachment and entry 
into the target cells. After binding of gp120 with CD4 and its coreceptor, gp41 undergoes 
a cascade of conformation changes, as described subsequently, to expose its fusion 
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 peptide, which will insert into the target cell membrane and bring the cell membrane 
close to the viral membrane to allow fusion proceeding. 
 
Two regulatory proteins Tat and Rev are encoded by HIV-1 RNA genome. Tat is a 
transcriptional transactivator which can increase HIV-1 mRNA production about 100 fold 
(48). Tat primarily enhances the processitivity of transcribing polymerase and, in the 
absence of Tat protein, polymerase can only generate short transcripts of a few hundred 
nucleotides.  Tat forms a complex with Cyclin T, which recognizes the transactivation 
response element (TAR) on the HIV-1 RNA genome. The Cyclin T-Tat complex further 
recruits a serine kinase CDK 9, which phosphorylates the carboxyl terminal domain of 
RNA polymerase II and converts it from the initiating form to the elongation form (49-
51).  Rev protein can bind to the Rev response element (RRE) in all unspliced or 
incompletely spliced RNA transcripts and targets them to the cytoplasm for translation 
(52).  Therefore, Rev is necessary for the late-phase viral protein (Gag, Pol, Env, Vif, Vpr, 
and Vpu) production. 
 
Four accessory proteins (Nef, Vif, Vpr, and Vpu) are encoded in the HIV-1 genome and 
these accessory proteins modify the local microenvironment in the infected cells to 
promote virus survival (48). Nef can increase the endocytosis of CD4 from the membrane 
surface of infected cells by targeting CD4 to clathrin-coated pits for internalization 
through interaction with the AP-2 adaptor complex (53). Nef also downregulates surface 
expression of MHC-I molecules, especially HLA-A and HLA-B, although the exact 
mechanism is less clear (54). Vpu recruits CD4 in the endoplasmic reticulum (ER) to 
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 ubiquitin-proteasome degradation pathway and therefore reduces CD4 en route to the 
plasma membrane (55).  Vpu was also found to antagonize the inhibition of HIV-1 
release from infected cells by CD137 (56). Vif protein is essential for virus replication in 
primary T cells, macrophages, and certain cell lines. However, vif mutation does not 
affect virus infectivity when the virus is produced in permissive cells, suggesting these 
cells lack an antiviral phenotype that can be suppressed by Vif in the non-permissive cells.  
By comparing the mRNA profile of permissive cells with non-permissive cells using 
complementary DNA subtraction strategy, the human gene, apolipoprotein B mRNA-
editing enzyme catalytic polypeptide-like 3G (APOBEC3G) was identified as the cellular 
factor in non-permissive cells to inhibit production of infectious particles in the absence 
of Vif (57). Vif can efficiently target the antiviral protein APOBEC3G/F for proteasomal 
degradation, thereby preventing its encapsulation into the virions and protecting the viral 
genome from cytidine deamination in the newly synthesized minus DNA strand (58). Vpr 
is a multifunctional accessory protein. It mediates the nuclear localization of pre-
integration complex (PIC), thereby allowing HIV-1 infection of nondividing mammalian 
cells like macrophages (59). Also, Vpr can arrest infected cells in G2/M phase and 
thereby promote transcription from the HIV-1 LTR (60).  There is one more accessory 
gene in HIV-2, termed vpx, which seems to be derived from recombination or duplication 
of vpr. Its product can promote HIV-1 infection of dendritic and myeloid cells by 
counteracting host restriction factor SAMHD1 (61-63).  
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 An overview of HIV life cycle 
Virus infection begins with virion entry into target cells through the interaction of viral 
envelope protein gp120 with its receptor CD4. The binding of gp120 to CD4 induces the 
exposure of a second binding site for its coreceptor CCR5 or CXCR4. Following binding, 
the gp41 transmembrane subunit of the envelope protein undergoes a dramatic 
conformational change to mediate virus-cell membrane fusion, enabling the virus capsid 
to enter the cell. After entry into the cell, the virus capsid is removed in the cytoplasm 
and the genomic RNA is reverse transcribed by reverse transcriptase (RT) into a linear 
double-strand DNA with a central DNA flap.  Viral DNA is then transported into the 
nucleus for integration into host genomic DNA, which occurs via a serial coordinated 
reactions by integrase (IN).  The integrated HIV DNA is called provirus. The provirus 
can exist in a latent or productive state, determined by genetic factors of the viral strain, 
the type of cell infected, and the production of specific host cell proteins (64). Latent 
infection of resting CD4+ T cells provides a mechanism of lifelong persistence of HIV-1, 
even in the presence of highly active antiretroviral therapy (HAART) (65).  Activation of 
host cells induces transcription of viral mRNAs from integrated proviral DNA. Viral 
mRNAs are then transported into the cytoplasm for translation into structural and 
regulatory viral proteins and for assembly into new viral particles as genetic materials. 
Newly assembled virions pass through the plasma membrane, acquiring its lipid envelope. 
Concomitant with or immediately following budding, virions mature to become 
infectious, ready to infect target cells and begin a new cycle (66).  
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 HIV Entry 
HIV-1 virus has developed an intricate mechanism to efficiently deliver its genome into 
its target cells while avoiding the host immune defense against itself (Figure 1.3). Env 
protein is the key player of this delicate mechanism to mediate virus entry into the target 
cells.    
  
Structure of Env  
The mature Env protein forms a trimer of heterodimer of gp120 and gp41 that are non-
covalently associated (46, 47). Gp120 is heavily glycosylated, with about half of the 
molecular mass contributed by N-linked glycans. Additionally, there is evidence that O-
linked glycosylation is present on HIV-1 Env protein (67). Extensive glycosylation 
creates a glycan shield and is an effective mechanism for HIV-1 to evade the attack from 
the host immune system, given the fact that the glycan adducts are human in composition. 
In this regard, HIV-1 can escape neutralization by masking vulnerable protein sites via 
glycosylation and thereby altering immunogenicity (68, 69).  The low number of Env 
spikes (8-10 on average)  on the surface of wild-type HIV virions (70), and consequently 
the low density of spikes on the virion surface provide another mechanism for the virus to 
evade the humoral immune response by impeding the bivalent binding of Env-specific 
antibodies (71). 
 
Gp120 determines the virus specificity for the target cell through recognition of its CD4 
receptor as well as chemokine coreceptor on the target cell. The gp120 subunit is  
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Figure 1.3.  Overview of HIV entry (Adapted from Wilen CB, et al, 2012 (72)). Env is composed 
of surface subunit gp120 and transmembrane subunit gp41 (resting state, 1). Gp120 binding of 
receptor CD4 (step 2) exposes the binding site for one of its coreceptors, CCR5 or CXCR4. After 
coreceptor binding (step 3), the fusion peptide of gp41 is activated and insert into the target cell 
membrane. 6-helix bundle formation (step 4) then drives the completion of membrane fusion. 
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 composed of five constant domains (C1-C5) interspersed with five variable domains (V1-
V5). All variable domains except for V5 form loops that protrude from the protein 
surface with disulfide bonds formed at the base (73). Sequence variations in the variable 
domains result from recombination, point mutation, insertion or deletion. Thus the length 
of the loops is not constant either, with V1/V2 being the most variable in length (74). 
V1/V2 loops were observed to elongate over the course of HIV infection, suggesting that 
the increased V1/V2 length may further help evade the host immune response (75).  The 
V3 loop is a critical determinant of coreceptor usage. It has been shown that a V3 region 
swap between a CCR5 (R5) virus and a CXCR4 (X4) virus can change the tropism of 
HIV-1 virus correspondingly (76).   Indeed, as few as one or two specific mutations in V3 
region are sufficient to convert the coreceptor usage (77).  There are also other sites that 
clearly affect the coreceptor usage of HIV-1. For example, HIV-1 virus tropism changes 
with mutations in V1 and V2 or C4 regions of gp120 (78, 79). The CD4 binding site of 
gp120 forms a recessed pocket involving conserved residues from discontinuous 
segments surrounding by variable residues (80). The CD4-gp120 interface contains two 
unusually large cavities. One cavity is lined with hydrophilic residues derived equally 
from CD4 and gp120 whereas the other cavity, named the “Phe43” cavity, is a docking 
site for the CD4 residue, Phe 43.  The CD4-bound gp120 core, with N- and C-terminal 
deletions, partial removal of V1/V2 and V3 loops,  consists of an inner domain, an outer 
domain and a four-stranded bridging sheet in between (80).   
 
Gp41 is the transmembrane subunit of Env protein, anchoring the Env protein on the 
surface of the viral lipid membrane. The gp41 subunit is composed of three major 
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 domains: an extracellular domain, a transmembrane domain and a cytoplasmic domain. 
The extracellular domain can be further divided into four functional segments: the N-
terminal fusion peptide, the N-terminal α-helix, the C-terminal α-helix, and membrane 
proximal external region (MPER). A short loop between the N-terminal α-helix and the 
C-terminal α-helix is immunodominant and stimulates the production of antibodies 
lacking neutralizing activity (81). Binding of gp120 to CD4 can induce a series of 
conformational changes, leading to the exposure of the hydrophobic fusion peptide and 
its penetration into the target cell membrane. The formation of an anti-parallel 6-helix 
bundle structure by the N-terminal α-helix and the C-terminal α-helix, with the latter 
padding outside onto the former, leads to the close apposition of the viral membrane and 
the cell membrane. The interaction between the fusion peptide proximal region (FPPR) 
and MPER may also contribute favorably to the energetics of the fusion process (82).  
 
In the absence of a high-resolution X-ray crystallographic structures available for trimeric 
Env currently, cryoelectron tomography studies on Env proteins from HIV-1 or SIV 
strains have shed light on the molecular architecture of trimeric Env displayed on virions 
(Figure 1.1) (83-87). The Roux group reported that trimeric SIV Env forms a globular 
tripod-like spike, with three legs splayed out on the viral membrane surface (88).  Using 
similar electron tomographic analysis, however, Zanetti and coworkers concludes that 
Env spike resemble a mushroom with a single stalk protruding from the viral membrane 
(89). There are also different views on the arrangement of gp41, one group reporting a 
compact spike stem (35) and another group supporting a tripod structure (90). 
Interestingly, the Env spike from SIVmac239 displays a closed conformation whereas the 
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 Env spike from SIV CP-MAC, a CD4-independent strain, assumes a constitutively open 
conformation. The open conformation of the Env spike from SIV CP-MAC is 
comparable to that of HIV-1 BaL when it is complexed with soluble CD4 and the CD4i 
antibody 17b (83).  The differences reported by different groups clearly demonstrate the 
complexity of molecular architectures of trimeric Env and imply the conformational 
plasticity of the Env spike, including variable quaternary structures. However, very recent 
data shows the cleavage of Env protein into gp120 and gp41 significantly affects the 
conformation the trimers assume. Cleaved Env trimers with trimer-stabilizing 
modification adopt homogeneous conformations expressing quaternary structure-
dependent epitopes and neutralizing epitopes whereas uncleaved Env trimers are more 
structurally heterogeneous with exposure of non-neutralizing epitopes in the absence of 
multiple neutralizing epitopes (91). These trimers have been used just recently to reveal 
additional details of glycosylated HIV-1 Env trimers by cryo-EM at 5.8 Å resolution (92) 
and by X-ray crystallography at 4.7 Å resolution (93). Of note, all but 4 residues of the 
MPER segment were deleted in order to increase the solubility and the conformational 
homogeneity of the Env trimers (91-93). 
 
Env conformational changes during HIV entry  
HIV-1 entry is initiated by the binding of gp120 to CD4. By comparing the conformation 
of gp120 in complex with CD4 and the unliganded state, several features of structural 
rearrangements of gp120 are revealed (94-99). First, the V1/V2 loops may be displaced 
laterally while the V3 loop is lifted up from the top, which may help form the coreceptor 
binding site (90).  In the CD4-bound state, the bridge sheet in gp120 is formed by four 
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 antiparallel beta sheets from the outer domain and inner domain of gp120 (100). The 
newly formed bridge sheet may be part of the coreceptor binding site. After binding to 
CD4 together with coreceptor or mAb 17b, which binds to the coreceptor binding site, 
gp120 undergoes an outward rotation and displacement and the Env trimer assumes an 
open conformation compared to the closed conformation of native Env trimer (83, 87). 
The outward rotation of gp120 reveals gp41 and exposes the fusion peptide to the target 
cell membrane (Figure 1.3). After insertion of the fusion peptide into the target cell 
membrane, the C-terminal α-helices fold back in an antiparallel fashion onto the trimeric 
coiled-coil core assembled by the N-terminal α-helices, thus forming a 6-helix bundle. 
The formation of the 6-helix bundle brings the viral membrane and the cell membrane 
into close apposition for fusion to occur (Figure 1.3). 
 
Antibody responses during HIV-1 infection 
During acute HIV-1 infection, robust antibody responses are generated against both the 
gp120 and gp41 subunit of the Env protein. Unfortunately, these antibodies target the 
nonneutralizing epitopes of Env protein and provide little, if any, protective effect against 
disease progression. Within a few weeks of infection, neutralizing antibodies arise 
against the variable loops V1, V2, V3 or V4. However, the breadth of these antibody 
specificities is quite narrow and plasma viruses can quickly evolve to escape 
neutralization (101). Although the host immune system can develop new antibody 
responses against the escaped viruses, the antibody responses always lag behind the virus 
evolution, thereby conferring little effect on virus control. However, in a minority of 
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 patients, some broadly neutralizing antibodies are generated after several years of chronic 
infection (102). These antibodies target conserved regions of Env protein and are capable 
of neutralizing heterologous viruses from different subtypes or even different groups.  
Additionally, these broadly neutralizing antibodies have been demonstrated in non-
human primate models or humanized mice to be able to confer protection against virus 
infection (103-105). In a recent study, analysis of sera from 78 unusual asymptomatic but 
HIV-1-infected patients revealed that 27% exhibited anti-MPER neutralizing activity and 
8% contained 10E8-like broadly neutralizing antibodies (106). 
 
Broadly neutralizing antibodies against HIV-1 
Env protein is the sole target of broadly neutralizing antibodies. That said, for many 
years, only a few broadly neutralizing antibodies were isolated from HIV-1 patients: b12 
targeting the CD4 binding site of gp120 (107), 2F5 and 4E10 targeting the MPER region 
of gp41 (108, 109), and 2G12 targeting a gp120 glycan associated site (110). In recent 
years, with the development of high throughput technologies, additional broadly 
neutralizing antibodies with higher potency and greater breath of coverage were 
isolated from HIV-1 patients.  Figure 1.4 shows the binding sites of the broadly 
neutralizing antibodies on the HIV-1 Env trimer model. 
 
First generation broadly neutralizing monoclonal antibodies 
The first broadly neutralizing antibody, b12, was isolated from a long-term non-
progressor infected with a clade B strain of HIV-1 using combinatorial phage display  
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Figure 1.4. Isolated broadly neutralizing antibodies and their binding sites on Env trimer model 
(Adapted from Corti D, Lanzavecchia A 2013 (111)). On top of the lipid bilayer (yellow) sits the 
Env trimer which is derived from the Electron Microscopy Data Bank code EM-5019. Two of the 
three gp120 subunits are shown. The epitopes of broadly neutralizing antibodies as well as the 
locations of V1/V2 and V3 loops are labeled correspondingly. The glycans (red) are modeled 
based on the unliganded YU gp120 core, and the glycans targeted by PG9 and PG128 (among 
PGT125-131 group) are highlighted in various colors. 
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 method in 1992 (112, 113). This antibody can neutralize approximately 75% of clade B 
primary isolates and around 50% of primary isolates from clades A, C and D. This 
antibody, however, is produced artificially by random pairing of antibody heavy chains 
and light chains from phage display libraries. Around the same time, using hybridoma 
technology, several other broadly neutralizing antibodies were generated from peripheral  
blood lymphocytes. Among these, 2G12 recognizes the N-linked carbohydrates in the C2, 
C3, V4, and C4 regions of gp120 while 2F5 and 4E10 target adjacent and contiguous 
epitopes in the MPER region of gp41 (109, 110, 114, 115). Another less potent 
neutralizing antibody also targeting the MPER region, Z13 was derived from the Fab 
phage display library using bone marrow RNA from an HIV-1 infected patient with 
broad sera neutralizing activity (115). Through mutations in the complementarity 
determining region (CDR) L3 region, Z13 was further engineered to have 100-fold 
increase in binding affinity for the MPER peptides as well as neutralization potency 
against tested HIV-1 strains. This affinity-enhanced variant is termed Z13e1 (116).  
 
Second generation broadly neutralizing monoclonal antibodies 
For a long period, b12, 2G12, 2F5, 4E10, and Z13e1 were the only available broadly 
neutralizing antibodies. The inability to re-isolate b12-like broadly neutralizing antibody 
from HIV-1 patients, together with the finding that the broad serum neutralizing activity 
from elite controller results from multiple neutralizing antibody specificities against 
different epitopes on gp120 (117), casts doubt on whether the human immune system is 
capable of making broadly neutralizing antibodies with great potency. The isolation of 
PG9 and PG16 through direct neutralization screening of secreted IgG from about 30,000 
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 activated memory B cells from an HIV-1 infected patient with broad serum neutralizing 
activity clears the doubt convincingly. PG9 and PG16 target a quaternary epitope 
involving gp120 v1/v2 loops as well as associated glycans (118). Compared to the first 
generation broadly neutralizing antibodies, these two monoclonal antibodies have the 
best neutralization breadth with an IC50 less than 1.0 ug/ml and exhibit 10-fold higher 
neutralization potency (118). Using the same high-throughput functional approach, a set 
of clonally related glycan-dependent monoclonal antibodies PGT121-123 and PGT125-
131, PGT135-137, and PGT141-145, targeting the quaternary epitopes around the V3 
region of gp120, were recovered from four elite neutralizers (HIV-1 patients with 
exceptional breadth and potency of serum neutralizing activity) with even higher 
neutralizing potency than PG9 and PG16 (119). The isolation of broadly neutralizing 
antibodies targeting the CD4 binding site of gp120 were also successful with structure-
informed design of the Env probe, termed resurface stabilized core 3 (RSC3), which 
retains the major contact surface for CD4, but removes all other antigenic epitopes on 
gp120. The resulting broadly neutralizing antibody VRC01 and its somatic variant 
VRC02 can neutralize 91% of tested viruses which represent all major HIV-1 circulating 
isolates and comprise viruses derived from acute and chronic HIV-1 infections. More 
importantly, VRC01 associates strongly with its corresponding serum in terms of 
neutralization breadth and potency, suggesting that VRC01–like specificity dominates the 
antibody profile of the serum.  Peripheral blood mononuclear cells from two additional 
HIV-1 patients were probed using the same strategy and two groups of VRC01-like 
antibodies, represented by VRC-PG04 and VRC-CH31, were recovered (120). Using a 
different probe 2CC-core, which is stabilized in the CD4-bound conformation, several 
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 broadly neutralizing antibodies were recovered, including 8ANC131, 12A12, and 
3BNC117. All these antibodies recognize the CD4 binding site of gp120 through their 
respective heavy chain by CD4 mimicry, similar to other CD4 binding site antibody 
VRC01, VRC-PG04, and VRC-CH31 (121). A new technology to isolate human 
monoclonal antibodies without the need of detailed information on specificity was 
developed to recover a new broadly neutralizing antibody recognizing the MPER region 
on gp41 (106). This new broadly neutralizing antibody, named 10E8, can neutralize 98% 
of tested viruses (106). 
 
Unusual features of broadly neutralizing monoclonal antibodies 
The rapidly expanding list of broadly neutralizing antibodies reveals four conserved sites 
of vulnerability on HIV-1 Env protein (107, 122-125), including the CD4 binding site, 
the V3 region, and the V1/V2 region, which are all part of gp120, as well as the MPER of 
gp41. The attempts to generate these broadly neutralizing antibodies with immunization, 
however, have not met with success, partly due to the non-canonical features of these 
broadly neutralizing antibodies, which pose tremendous challenges to vaccination 
strategies. For example, all these broadly neutralizing monoclonal antibodies contain high 
levels of somatic hypermutations and with up to 40% of amino acids in the heavy chain 
variable region divergent from the unmutated germline gene sequence for broadly 
neutralizing antibodies targeting CD4 binding site (126).  Even more surprisingly, many 
mutations occur in the framework regions (FWR) and these FWR mutations seem to be 
required for the broad and potent neutralization activities (127). Antibody domain 
exchange was originally proposed as an immunological solution to the high-affinity 
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 recognition of repeating carbohydrate on the surface of Env protein. However, more 
recent isolation of additional glycan-dependent broadly neutralizing antibody such as 
PG9 and PG16 suggests the unusual structure is not required (118, 119). Lipid binding 
and autoreactivity were considered the common features for the broadly neutralizing 
antibodies targeting the MPER region, possibly mediated by the hydrophobic residues in 
the long CDRH3 loops. The recently discovered broadly neutralizing antibody 10E8, 
however, lacks these unusual characteristics (106). With more broadly neutralizing 
antibodies to be isolated, further clarity of these features essential for these broadly 
neutralizing antibodies will be provided.  
   
Challenges in HIV-1 vaccine development 
The overall failure to develop a safe and effective vaccine to control the global HIV-1 
pandemic reflects the extensive mechanisms that HIV-1 has evolved to escape both 
humoral and cellular immune responses (128-136).  Activated CD4+ T helper cells, which 
coordinate the activities of the CTL and B cell responses through their co-stimulatory 
activities (137, 138) including the release of various cytokines (139, 140), are the direct 
targets of HIV-1 infection (141). The enormous sequence variability of HIV-1 strains 
within and between infected individuals not only makes it a challenge to select an optimal 
target for vaccination, but also confers on the virus the advantage of rapid escape from 
effective immune responses (142).  Latent reservoirs are rapidly established in primary 
HIV-1 infections and spare viral integrants from the pressures of host cellular responses 
as well as aggressive drug treatments, underscoring the importance of developing an 
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 antibody-based HIV-1 vaccine capable of preventing HIV-1 infection (143, 144). 
Unfortunately, HIV-1 has also established several mechanisms to counteract the effect of 
neutralizing antibodies. First, trimerization of Env proteins and the non-covalent 
interaction between gp120 and gp41 can occlude some conserved domains within the 
oligomer, rendering the antibodies targeting them unable to neutralize HIV-1 infection 
(145, 146). Second, the extensive N-linked glycosylation, as noted above, prevents 
exposure of many underlying epitopes via a glycan shield (147-150). Third, the variable 
loops on the outer surface of the envelope protein may direct immune responses toward 
those viral sites, which in turn can be easily mutated without obvious viral fitness cost 
(151, 152). Last, upon CD4 binding, some neutralizing epitopes may be exposed only 
transiently during the conformational changes accompanying the fusion process, 
therefore rendering those targets largely inaccessible to neutralizing antibodies. In 
essence such sites provide a kinetic shield whereby the virus can evade the immune 
detection (153). 
 
The MPER as an important target for vaccine development 
Among other proteins or peptides that are targeted for the development of antibody-based 
vaccines, the MPER of gp41 serves as an attractive candidate immunogen due to its 
sequence conservation among different subtypes of HIV-1 and the linear nature of the 
neutralizing epitopes defined to date. The MPER has been implicated in Env-mediated 
viral membrane fusion and entry through investigation of the effects of mutations or 
deletions in this region (154-156). Chapter 2 defined the role of the gp41 MPER in 
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 hemifusion and fusion futher, identifying a central hinge therein with tandom joints 
central for the conformational flexibility during fusion. Other MPER epitopes distinct 
from that of 2F5 and 4E10 might also be targeted by neutralizing antibodies in sera from 
HIV-1 infected individuals (157-159). 10E8, the broadly neutralizing antibodies recently 
isolated from the peripheral memory B cells of the HIV-infected patients, demonstrates 
much higher neutralizing potency with a slightly more extended epitope specificity than 
4E10  but still involving tryptophan 672 and phenylalanine 673 as well as tryptophan 680 
(Based on HxB2 numbering) (106). Interestingly, the central hinge region of the MPER 
which is well conserved except for the two flanking residues at position 671 and 674 is an 
essential target for both 4E10 and 10E8, suggesting its indispensable function in virus 
fitness. Hence, in Chapter 2, we explored the effect of the mutations in the MPER hinge 
region on Env-mediated membrane fusion process as well as the virus infectivity in detail. 
 
Attempts to generate 2F5- or 4E10-like MPER-specific antibodies, however, have been 
unsuccessful thus far. Some groups attempted to present the 2F5 epitope in the context of 
a chimeric virus, resulting in the generation of sera capable of binding to 2F5 epitope 
strongly, but with little, if any, neutralizing activity (109, 160-163). Others using fusion 
proteins containing the 2F5 epitope also failed to elicit broadly neutralizing antibodies 
against HIV-1 (164-166). Similarly, peptide-based vaccine formulations of 2F5 epitope-
containing peptide conjugated to keyhole limpet hemocyanin (KLH) did not generate 
antibodies with broad neutralizing activity (167, 168). Based on these studies, it is 
postulated that the MPER must have been presented to the immune system in an 
irrelevant (i.e. non-native) conformation. Even so, two recent studies using synthetic 
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 epitope-scaffolds exhibiting high epitope structural mimicry to present 2F5/4E10 
epitopes likewise failed to elicit antibodies with broadly neutralizing activity (169, 170). 
In this regard, studies on the neutralization mechanisms of 2F5 and 4E10 suggest that 
their interaction with the viral membrane, mediated by specific hydrophobic residues on 
the tip of the 2F5 and 4E10 CDR H3, may be essential for the broad neutralizing activity 
(171-177). It is generally believed that both structure-specific recognition of the MPER 
and interaction with the viral lipid membrane are required for the neutralization activities 
of 2F5 and 4E10. Most compellingly, using biophysical methods, Kim et al showed that 
MPER recognition by 2F5 is mediated by a paratope more extensive than core binding 
site contacts alone and the lipid interaction of CDRH3 is critical for 2F5 neutralization 
activity (178). Together with the observation that the 2F5 and 4E10 epitopes are better 
presented in a lipid environment (179), these findings favor a strategy of immunogen 
design whereby the MPER is displayed in the context of viral membrane mimics.  
 
To date, however, VLP and viral vectors with MPER grafted onto viral membrane 
proteins as immunogen carriers have been unsuccessful in generating BNAbs. This may 
be due to the immunodominance of endogenous protein expression on such particles 
which prevents targeted immunity as well as the structural nature of the MPER which is 
embedded in lipid making it more stealth (180, 181). In addition, the structural 
configuration of the MPER when grafted onto a surface viral protein is uncertain. 
Therefore, in chapter 3, PEGylated liposomes were used to embed and present the MPER 
to the immune system in a nanovaccine formulation with explicit structural determination 
performed to link immunogenicity with MPER conformation. Subsequently, following 
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 MPER immunizations we analyzed the antibody repertoire both by characterization of the 
elicited bulk sera IgG and at the single memory B cell and plasma cell levels using a high 
throughput microengraving platform. 
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 Abstract 
HIV-1 (human immunodeficiency virus type 1) uses its trimeric gp160 envelope (Env) 
protein consisting of non-covalently associated gp120 and gp41 subunits to mediate entry 
into human T lymphocytes. A facile virus fusion mechanism compensates for the sparse 
Env copy number observed on viral particles and includes a 22-amino-acid, lentivirus-
specific adaptation at the gp41 base (amino acid residues 662–683), termed the 
membrane proximal external region (MPER). We show by NMR and EPR that the MPER 
consists of a structurally conserved pair of viral lipid-immersed helices separated by a 
hinge with tandem joints that can be locked by capping residues between helices. This 
design fosters efficient HIV-1 fusion via interconverting structures while, at the same 
time, affording immune escape. Disruption of both joints by double alanine mutations at 
Env positions 671 and 674 (AA) results in attenuation of Env-mediated cell–cell fusion 
and hemifusion, as well as viral infectivity mediated by both CD4-dependent and CD4-
independent viruses. The potential mechanism of disruption was revealed by structural 
analysis of MPER conformational changes induced by AA mutation. A deeper acyl 
chain-buried MPER middle section and the elimination of cross-hinge rigid-body motion 
almost certainly impede requisite structural rearrangements during the fusion process, 
explaining the absence of MPER AA variants among all known naturally occurring HIV-
1 viral sequences. Furthermore, those broadly neutralization antibodies directed against 
the HIV-1 MPER exploit the tandem joint architecture involving helix capping, thereby 
disrupting hinge function. 
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 Introduction 
Lentiviruses such as HIV-1 (human immunodeficiency virus type 1), the causative agent 
of acquired immunodeficiency syndrome (AIDS), are encapsulated in a membrane 
derived from the infected host cell as virus buds (reviewed in Refs. (1) and (2)). A 
trimeric Env gp160 spike consisting of three pairs of non-covalently associated gp120 
and gp41 subunits is the only viral protein on the HIV-1 membrane. The Env gp120 
mediates attachment and entry into human CD4+ T lymphocytes upon binding its primary 
cellular receptor CD4 and CCR5 or CXCR4 co-receptor. Viral infectivity is dependent on 
membrane fusion between HIV-1 and the host cell through formation of a gp41 six-helix-
bundle complex (3-5). The efficiency of this mechanism is especially critical, given fewer 
than 12 copies of Env clustered on each viral particle (6). 
 
The membrane proximal external region (MPER) is a tryptophan-rich segment located at 
the base of the gp41 subunit and appears to destabilize the viral membrane during the 
fusion process (7, 8). Deletion of the HIV-1 MPER, or concurrent mutation of three 
conserved tryptophan residues on its N-terminal helix to alanines, abolishes membrane 
fusion activity (9) and (10). However, the presence of these conserved tryptophans alone 
is not sufficient to support the viral fusion activity (7). Other MPER residues, even the 
exposed, primarily hydrophilic ones, may also be involved despite sequence variability 
therein. Previously, we solved the solution structure of a clade B HxB2 strain MPER 
peptide in detergent micelle with an unusual helix–hinge–helix motif (11). Interestingly, 
the central hinge region is the target of several broadly neutralizing antibodies (BNAbs), 
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 including 4E10, 10E8 and Z13e1 (12-14). Here, we provide detailed structural and 
functional results on this specialized hinge region relating to its potentially important role 
during the intermediate stages of the HIV membrane fusion process. 
 
Results and Discussion 
MPER sequence conservation and limited variability 
Bioinformatics studies show that, while considerably conserved within each lentivirus 
group, the MPER sequences from HIV-1 and its ancestor SIV-CPZ (chimpanzee) are 
distinctive from those of HIV-2 and their related SIV-MAC (macaque) and SIV-AGM 
(African green monkey) sequences and are distant from non-primate lentiviruses (Figure 
2.1). As shown in Figures. 2.1b and 2.2a, the HIV-1 MPER is highly conserved across 
different clades. Structurally, the clade B HxB2 MPER peptide in dodecyl-
phosphocholine (DPC) detergent micelle shows a helix–hinge–helix motif dictated by the 
segment's unique amphipathic pattern (Figure 2.2b), with the membrane-buried residues 
mostly conserved and solvent-exposed residues relatively more variable. This pattern is 
prominent at the central hinge region, where the two key epitope residues for BNAb 
4E10 and 10E8, W672 and F673, are essentially invariant and buried in the membrane, 
while the exposed N671 and N/D674, key epitope residues for Z13e1, manifest 
significant sequence variability (Figure 2.2b and c). Using the “Motif-finder” software 
(15) and Los Alamos HIV database, we have identified all 36 amino acid residue 
combinations at the 671 and 674 positions. This is a surprisingly small number taken  
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   Figure 2.1. Comparison of MPER 
segments from nine groups of lentiviruses. 
The lentiviral segments, 23 amino acid 
long, N-terminal to their respective 
annotated transmembrane helices were 
extracted from SwissProt Database. (a) 
Sequence alignment with colored residues 
being identical with the reference 
sequence (HIV-1 HxB2). (b) Logos 
showing conservation within each of the 
nine lentivirus groups. The extremely 
conserved 3650 SIV sequences from 
rhesus macaque (SIV-MAC) is a result of 
infection in research primate centers. 
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Figure 2.2. Sequence conservation and variation of HIV-1 MPER. (a) Amino acid sequences of 
MPER peptides used for structural studies, with conserved residues colored red. (b) HxB2 MPER 
structure in a DPC detergent micelle with conserved and variable residues colored according to 
the scale shown. (c) Population of amino acid combinations at the 671 and 674 residue positions 
at the central hinge region, with BlockLogo sequence conservation diagram of the 671–674 
segment shown as an inset at the top and conventional Shannon entropy representation of 
individual amino acid position variability at the bottom. 
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 from 21,967 HIV-1 strain sequences across all major clades (Figure 2.2c), and the residue 
types are dominated by asparagine, aspartate, serine and threonine (NDST set) (Table 
2.1). 
 
Hinge mutations impact HIV-1 viral infectivity 
To determine the functional role of the MPER hinge region and investigate the impact of 
sequence variations at residues 671 and/or 674 on virus entry, we produced viruses 
pseudotyped with MPER mutants by co-transfection of 293T cells with an Env-deficient 
HIV-1 (pSG3ΔEnv) backbone and an Env-expressing plasmid. The infectivity of 
pseudotyped viruses was then determined in TZM-bl (CD4+CXCR4+CCR5+) cells and 
read out as RLU (relative light units). The mutations of the HIV-1 Con089 clade C strain 
were generated by changing serine S671 and S674 residues (SS) in the wild-type (WT) 
sequence to NN, NG, NA and AA, respectively. Likewise, T671 and D674 (TD) of the 
WT Env from the clade B CAAN strain were mutated to DD, ND and SD. All except the 
AA mutations represent combinations found in naturally occurring HIV strains (Figure 
2.2c). 
 
Figure 2.3a shows that changing the residue in the WT sequence at these two amino acid 
positions to commonly represented residues (such as N, D, S or T) was well tolerated by 
the mutant pseudoviruses. In contrast, viral infectivity was reduced 6-fold for the non-  
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Table 2.1. Sequence (singly) variability of residues 671 and 674 in all HIV-1 strains 
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Figure 2.3. HIV-1 pseudovirus infectivity affected by AA mutations. (a) Infectivity of 
pseudoviruses harboring the Env mutations at positions 671 and 674. Comparable number of viral 
particles were used as determined by p24 Elisa. (b) Titration (log10) of Con089 and HxB2 Env 
WT or mutant pseudoviruses on TZM-bl cells. Mean and standard deviation of each dilution is 
shown. (c) Dose-dependent infectivity of CD4-independent ADA/Hx(197) pseudoviruses on 
CD4+ CCR5+ TZM-bl cells and CD4− Cf2Th/Syn CCR5 cells. The inset shows anti-gp120 mAb 
Western-blot of ADA/Hx(197) Env from pseudovirus. 
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 native AA mutation. Serial dilutions of Env-pseudotyped virus stocks with AA mutants 
from both Con089 and HxB2 strains further confirmed the effect of hinge region AA 
mutation on virus infectivity in TZM-bl cells (Figure 2.3b). The block to virus infectivity 
was greater with the AA mutation in the CXCR4-dependent strain HxB2 (reduction by 
more than 10-fold) but nonetheless significant (6- to 7-fold reduction) in both CCR5-
dependent Con089 (Figure 2.3b) and PB7 strains (data not shown), indicating that the 
attenuation of viral infectivity was independent of co-receptor usage. Note the log10 
scale used for both x- and y-axes. 
 
One possible explanation for the reduced viral infectivity might be linked to structural 
changes within the gp120/gp41 trimer induced by the AA mutation in the MPER 
impacting receptor binding. This possibility was excluded by examining an AA mutant of 
the CD4-independent chimeric strain, ADA/Hx(197) (16). ADA/Hx-AA mutant resulted 
in a significantly decreased capacity to infect both CD4+ TZM-bl (Figure 2.3c, top) and 
CD4− Cf2Th/Syn CCR5 (Figure 2.3c, bottom) cells (~ 70-fold reduction from WT). Thus, 
it appears that the AA mutation effect is significantly more pronounced in a CD4-
independent strain. In addition, no effects of this AA mutation on the efficiency of gp160 
envelope protein precursor processing to gp120 or expression level were observed on 
these pseudoviruses (Figure 2.3c, inset). 
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 Double alanine MPER mutant affects viral membrane fusion 
We next examined the effect of AA mutation on gp41-mediated fusion by a fluorescence 
cell–cell fusion assay. Env-expressing 293T effector cells stained with cytoplasmic dye 
Calcein-AM (green) were co-cultured with 3T3.CD4.CCR5 target cells stained with 
CellTracker orange CMTMR (red), and the exchange of cytoplasmic dyes between 
effector and target cells was monitored by fluorescence microscopy. The JRFL-AA 
mutant exhibited both reduced numbers and sizes of syncytia (appearing orange/yellow) 
at 4-h co-culture compared to WT (Figure 2.4a, top row), at levels comparable to the 
JRFL cleavage (−) negative control. A similar observation was made with ADA-AA 
compared to ADA-WT at 4 h. However, using bright field illumination at 24 h, while 
syncytia in JRFL-AA were significantly smaller than JFRL-WT syncytia (Figure 2.4a, 
bottom row), the ADA-WT and ADA-AA syncytia were more comparable (data not 
shown), arguing that MPER function may be critical for early fusion events. This 
possibility was confirmed in subsequent lipid mixing/hemifusion assays below. 
 
To quantitatively assess fusion efficiency, we utilized TZM-bl cells expressing luciferase 
under the control of the HIV long terminal repeat promoter responsive to HIV Tat as 
targets. The results confirmed impairment of cell–cell fusion by AA mutation in the 
MPER of JRFL and ADA strains. Fusion efficiency was reduced by ~ 50% in the first 6 h 
in both strains (Figure 2.4b). The reduced fusion efficiency was independent of surface 
expression level and envelope protein precursor processing. To further study the fusion 
block at the early lipid mixing/hemifusion phase, we used membrane probes in an  
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Figure 2.4. Env-mediated fusion impaired by AA mutations. (a) Qualitative microscopy analysis 
of cell–cell fusion. Content mixing of Env-expressing 293T effector cells with 3T3.CD4.CCR5 
target cells. The top row shows the overlay of fluorescence images after co-incubation of 293T 
cells (green, Calcein) with 3T3.CD4.CCR5 cells (red, CMTMR) at 37 °C for 2 h. The bottom row 
shows representative bright field images collected 24 h after co-incubation at 37 °C. (b) Fusion 
kinetics of JRFL (top) or ADA (bottom) Env-expressing 293T cells with TZM-bl cells containing 
a Tat-driven luciferase reporter. (c) Hemifusion identified by lipid mixing between DiO-labeled 
293T cells (green) and DiI-labeled 3T3.CD4.CCR5 cells (red). The top row shows the overlay of 
fluorescence images collected 2 h after co-incubation at 37 °C. The bottom row shows the 
corresponding bright field images. (d) Quantitative lipid mixing efficiency of JRFL-AA relative 
to WT. Flow cytometric analysis of lipid-dye transfer between DiO-labeled 293T cells and DiD-
labeled TZM-bl cells were conducted. The percentage of lipid mixing activities were determined 
following the subtraction of background dye redistribution between empty vector-transfected 
effector and target cells, normalized to that of WT (100%) in three independent experiments. 
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 experiment where DiO-labeled Env-293T cells (green) were co-cultured with DiI-labeled 
3T3.CD4.CCR5 (red) target cells for 2 h. Figure 2.4c shows DiI-labeled individual cells 
associated with DiO-labeled effector cells and also transfected with a cleavage site 
defective Env as a negative control. Whereas extensive dye redistribution with numerous 
co-localization events (spotting on cell surfaces) was observed for JRFL-WT, reduced co-
localization for JRFL-AA was observed which indicated blocking of lipid mixing, similar 
to the JRFL cleavage (−) negative control. Using flow cytometry analysis to quantity the 
double fluorescence cells, we observed hemifusion to be reduced by ~ 50% for the JRFL-
AA compared to JRFL-WT (Figure 2.4d). Collectively, these findings document a 
selective detrimental effect of MPER AA mutation on viral fusion and infection. 
 
MPER helix–hinge–helix motif is a common feature in both clade B and clade C HIV-1 
strains 
To understand the impact of hinge residue variation at the 671 and 674 positions on 
MPER conformation, we carried out NMR and EPR spectroscopy studies on several 
native and mutant MPER peptides (Figure 2.2a). The solution structures of three clade C 
peptides, Con089, Du151.2 and ZM197M.PB7 in DPC micelles (Figure 2.5a and Table 
2.2), adopt the same helix–hinge–helix motif as the previously solved clade B HxB2 
peptide (11). These new peptides usedin NMR studies all contain five additional native 
N-terminal residues from the gp41 CHR (C-terminal heptad repeat), EQELL for clade B 
and EKDLL for clade C strains. As represented by the clade C Con089 peptide in DPC 
detergent micelles shown in Figure 2.5b, the N-terminal extension forms a fishhook-like  
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Figure 2.5. Solution structures of MPER peptides. (a) NMR structure ensembles of Con089, 
Du151.2, ZM197M.PB7 and HxB2-AA MPER peptides in DPC detergent micelles, 
superimposed by their N-terminal helices (666–672). (b) The additional CHR residues at the N-
terminal end of MPER, as represented here by the Con089 peptide in DPC micelles, all adopt a 
conserved beta turn stabilized by L661/L662 and W666. (c) Ribbon diagram of a representative 
HxB2-AA peptide with the side chains of alanine substituted residues colored pink. (d) The left 
panels show JNH RDC values with good correlation between Con089 and Du151.2 but weaker 
correlation between HxB2 and HxB2-AA. The right panels show difference in JNH RDC values 
(normalized according to fitted linear correlation parameters) between Con089 and Du151.2 and 
between HxB2 and HxB2-AA. The errors are derived from NMR amide peak position estimates. 
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   Table 2.2 NMR statistics 
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 turn stabilized by two conserved leucine residues L660 and L661 inserted into the 
membrane phase, as well as a hydrogen bond between the side-chain amide of W666 and 
the backbone carbonyl of L661. This N-terminal extension from CHR is highly mobile 
and apparently has little effect on the rest of the peptide structure. 
 
The statistical results of NMR structural calculations are summarized in Table 2.2, 
including residual dipolar coupling (RDC) constants measured using a DNA nanotube 
detergent-resistant alignment medium (17). The RDC values obtained from multiple JNH, 
JNCO, JCOCA and JCAHA quantitative J experiments are incompatible with a single 
alignment tensor for the entire MPER peptide. However, the N-terminal and C-terminal 
helical segments of these MPER peptides can be fitted with two independent alignment 
tensors, consistent with the flexibility afforded by the central hinge (Figure 2.5a). The 
highly mobile MPER N-terminal region (657–665) and the C-terminal residue (683), as 
well as the central hinge region (672–673), are excluded from RDC data analysis. The 
similarity of RDC alignment tensors between Con089 and Du151.2 confirmed that the 
two peptides have very similar orientations as they differ only by two residues at 671 and 
674 positions (Figures. 2.2a and 2.5a). RDC values for the clade C peptide ZM197M.PB7 
are rather different due to its distinctive charged residue distribution (Figure 2.2a), 
resulting in different alignment tensor in the DNA nanotube alignment medium. 
 
Distinctive conformation of MPER AA mutant peptide 
The structure of HxB2-AA peptide does not have the generally L-shaped bend as 
observed with the other MPER peptides (Figure 2.5a). In addition, the N-terminal helix is 
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 extended by one residue to F673, while the C-terminal helix is shortened by two residues 
at the N-terminal end (Figure 2.5c). This distorts the original central hinge region, 
resulting in an elongated and partially unstructured linker region between residues 674 
and 677. The alanine residues at 671 and 674 positions are not exposed to the solvent as 
is typical for other MPER peptides (Figure 2.5b and c). 
 
Measured JNH RDC values between HxB2 WT and HxB2-AA mutant peptides in DPC 
micelles show a weaker correlation with a reduced R2 value compared to that between 
Con089 and Du151.2 (Figure 2.5d, left panels), which have similar orientations. This is 
despite the fact that each pair differs only at residue positions 671 and 674 by the change 
of asparagine to serine or alanine and maintains the same charged residue distribution 
(Figure 2.2a). Thus, the RDC values from HxB2 and HxB2-AA mutant MPER peptides 
must diverge as a result of structural differences on the membrane surface, most 
noticeably near the distorted hinge regions (Figure 2.5d, right panels). The same patterns 
are observed for other RDC types, but JNH RDC values shown here are more accurate 
and easiest to measure experimentally. 
 
Atypical behavior of MPER AA mutant on membrane surface 
EPR immersion depth measurements for the three clade C MPER peptides, Con089, 
Du151.2 and ZM197M.PB7, also showed comparable overall structure and membrane 
immersion in POPC:POPG (4:1 by weight) liposomes (Figure 2.6a). Similar to HxB2 
(11), the acyl chain-facing and aqueous-facing side chains judging by their immersion 
depths alternate every third or fourth sequence position from 666 to 673 and from 675 to  
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Figure 2.6. Structural comparison with MPER AA mutant. (a) EPR membrane immersion depths 
of Con089, Du151.2, ZM197M.PB7 and HxB2-AA in liposomes. Depth values between − 5 Å to 
0 Å and larger than 0 Å correspond to lipid head-group region and acyl-chain region, 
respectively. The white-colored bars indicate complete exposure to aqueous phase (depth is less 
than − 5 Å). (b) NMR structure models of representative Con089, Du151.2, ZM197M.PB7 and 
HxB2-AA peptides on the membrane surface. The lipid head-group and acyl-chain regions are 
shown in light blue and yellow, respectively. Residues 671 and 674 are colored pink. The N-
terminal extended regions (657–661) are omitted for simplicity. (c) EPR DEER spectra of singly 
spin-labeled HxB2-AA MPER peptides at residue positions 670 (top), 678 (middle) and 681 
(bottom) showing spin–spin correlation consistent with peptide dimerization. (d) NMR 15N-
heteronuclear single quantum coherence spectra of HxB2-AA MPER in DPC micelles, showing 
broadening and disappearance of some backbone amide peaks at higher peptide concentrations 
consistent with aggregation. 
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 681, consistent with helical conformation. However, the immersion depth data are out of 
phase at residue position 674, supporting the helix–hinge–helix motif. Taken together, the 
helix–hinge–helix motif in MPER is likely a conserved feature in all HIV-1 clades and 
potentially the ancestral SIV from chimpanzee (Figure 2.1). 
 
In contrast, EPR immersion depth measurements show an altered membrane immersion 
pattern for HxB2-AA mutant as compared to other MPER peptides (Figure 2.6a). There 
are more residues buried in the aliphatic region and fewer residues with complete solvent 
exposure in the case of the HxB2-AA mutant. The depth pattern of Con089-AA mutant 
peptide was also an outlier (data not shown). Figure 2.6b shows the side views of the 
MPER peptides embedded in the membrane by incorporating EPR immersion depth 
restraints in the NMR structure calculations. The HxB2-AA mutant peptide has a deeply 
buried middle section, bending in a different orientation with respect to other native 
MPER peptides (Figure 2.5a and 2.6b). 
 
EPR double electron–electron resonance (DEER) spectra of singly spin-labeled HxB2-
AA MPER peptides at residue position W670, W678, or Y681 show detectable spin–spin 
distances (< 30 Å) consistent with peptide dimerization (Figure 2.6c). NMR results also 
suggest that the HxB2-AA MPER mutant tends to aggregate at high concentrations, as 
the amide backbone peaks become broadened and some of them disappeared (Figure 2.6d) 
even in DPC micelles. These changes were not observed for other native MPER peptides 
and can be attributed to the double substitution of asparagine at residue positions 671 and 
674 by alanines and the associated increase in hydrophobicity. 
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 Alternative N-capping of the MPER C-terminal helix 
How does the double alanine substitution of MPER 671/674 hinge residues functionally 
impact HIV-1 infection during the early membrane fusion stages (Figure 2.7a)? First, 
MPER hinge distortion and aggregation might alter gp41 trimer interface and indirectly 
induce structural change around the CD4 binding site in the pre-fusion state. However, 
this possibility cannot explain AA mutation effects on CD4-independent virus infectivity 
(Figure 2.3c). Alternatively, the AA mutation might destabilize gp41 6-helix bundle-
mediated membrane pore formation manifest in the post-fusion state. This is also unlikely 
given only minor contacts involving residues 671 and 674 in a six-helix-bundle structure 
including MPER segment (18). Third, the AA mutant MPER could impede the 
assembling of the gp41 six-helix bundle during the fusion intermediate stages, hindering 
the kinetics of the early membrane fusion process (Figure 2.7a) in agreement with our 
experimental findings and the structural implications discussed below. 
 
Native MPER 671 and 674 position residues overwhelmingly belong to the NDST set 
(Table 2.1), a prominent feature for all HIV-1, HIV-2 and SIV lentiviruses (Figure 2.1). 
The asparagine, aspartate, serine and threonine residues are favored as helix N-cap 
residues by forming side chain-to-main chain hydrogen bonds to stabilize the N-terminal 
end of alpha helices (19, 20). This is consistent with the breaking of N- and C-terminal 
helices of the MPER to adopt a helix–hinge–helix motif. Figure 2.7b shows backbone 
dihedral angle predictions based on observed NMR chemical shifts that reveal the 
breakage of helices in the 2F5-bound MPER (21-23) and the 4E10-bound MPER (24) at 
residue 671 and in the Z13e1-bound MPER (24) at residue 674. Helix breakage at residue 
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Figure 2.7. MPER conformation change during HIV membrane fusion. (a) Illustrations of 
the HIV fusion process following CD4 binding. Chemokine receptors are omitted at the 
pre-fusion stage and only one gp41 monomer is drawn in the intermediate stages for 
simplicity. MPER is highlighted in red. (b) Hinge conformation revealed by backbone 
dihedral angles for free and BNAb-bound HxB2 WT MPER derived from observed NMR 
chemical shifts, except for 10E8 where the angles are extracted from a crystal structure 
(PDB ID: 4G6F). The backbone dihedral angles extracted from unbound Con089 and 
HxB2-AA peptide NMR structures are shown for comparison. (c) Side-chain oxygen 
(green) to backbone amide (blue) hydrogen bonds observed in crystal structures of MPER 
bound to BNAbs: (top) between N671 and D674 in 10E8, (middle) between N671 and 
F673 in 4E10 (PDB ID: 2FX7) and (bottom) between D674 and T676 in Z13e1 (PDB ID: 
3FN0). (d) Orientation change of W672/F673 with respect to the membrane with different 
N-capping of the C-terminal helix in 10E8-bound and unbound MPER. 
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 671 is also observed in the X-ray crystal structure of the 10E8-bound MPER (13). Indeed, 
the side chains of MPER residues N671/D674 form hydrogen bonds to the backbone 
amides of the C-terminal helix residues in all of the aforementioned MPER-neutralizing 
antibody complexes (Figure 2.7c). Similar helix breakage at residue 674 can also be 
observed for unbound Con089 MPER peptides in DPC micelles, but not for HxB2-AA 
(Figure 2.7b). 
 
Helix N-capping has been shown to regulate kinetics of light-induced conformational 
changes in a PYP PAS domain (25), to correlate with allosteric activation in a cAMP 
receptor via helix breakage (26) and to maintain continuous curvature on the surface of a 
retroviral capsid via an inter-domain hydrogen bond (27). The first structural implication 
of our results is that the gp41 ectodomain could pivot in a rigid-body motion via the 
MPER central hinge region. The helix–hinge–helix motif, strengthened by the N-capped 
MPER C-terminal helix, could exert force on the lipid bilayer while, at the same time, 
adapting to membrane curvature during viral membrane fusion. Secondly, as shown in 
Figure 2.7d, the orientations of the two central residues, W672 and F673, relative to the 
membrane in relation to the helical break at either 671 (left) or 674 (right) joint position 
are strikingly different. It appears that the formation of a “sliding” hinge region, 
facilitated by helix N-capping at a pair of tandem joint positions of the MPER (Figure 
2.7b), could potentially promote lipid mixing by allowing such “rotary” motion of bulky 
aromatic residues with respect to the viral membrane. 
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 Since alanines have the highest helical propensity (28) but are unsuitable for capping a 
helix, double alanine mutations of MPER would disrupt the conserved helix–hinge–helix 
motif. Hence, in MPER-AA mutant, the extension of the N-terminal helix, deeper 
embedding in the membrane and inefficient C-terminal helix breaking, all contribute to 
reduced fusion activity and viral entry. In essence, the HIV-1 apparently incorporates a 
flexible and “fail-safe” tandem joint region, rationalizing why the double AA mutation in 
the MPER cannot exist in nature. However, by immobilizing the central hinge region, 
MPER-targeted BNAbs hinder HIV-1 fusion and infectivity. 
 
Materials and Methods 
Materials 
Lipids, liposome preparation, synthetic peptide production with and without spin-labels 
and procedures for GB1-MPER fusion protein production in Escherichia coli were 
previously described (11, 24). NMR stable isotope labels and d38-DPC detergent was 
purchased from Cambridge Isotope Laboratories (Andover, MA). Env-expressing 
plasmids JRFL delCT(+) (cytoplasmic tail deletion with WT cleavage site), JRFL 
delCT(−) (mutated cleavage site) and Tat-expressing plasmid pcTAT were kindly 
provided by Dr. Richard T. Wyatt (The Scripps Research Institute). Env-expressing 
plasmids to make CD4-independent pseudoviruses ADA/Hx(197) were kindly provided 
by Dr. Joseph G. Sodroski (Dana-Farber Cancer Institute). Con089 Env plasmid was 
kindly provided by Drs. Bart Haynes (Duke University) and Ronald Swanstrom 
(University of North Carolina at Chapel Hill). 293T cells were purchased from American 
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 Type Culture Collection. TZM-bl cell, 3T3.CD4.CCR5 cell and CD4− Cf2Th/Syn CCR5 
were obtained from the AIDS Research and Reference Reagent Program, National 
Institutes of Health. 
 
Preparation of pseudoviruses 
Single-round, recombinant HIV-1 viruses [Con089, CAAN, HxB2 and ADA/Hx(197)] 
were generated by transfection of 293T cells using an Env-deficient HIV-1 (pSG3ΔEnv) 
backbone and Env-expressing plasmid. Briefly, cells were seeded in 10-cm dish 
(approximately 3 × 106 cells per dish) and transfected the next day with pSG3ΔEnv and 
Env-expressing plasmid. Seventy-two hours after the transfection, virus-containing 
supernatants were collected, cleared of cell debris by low-speed centrifugation and 
filtered through 0.45-mm filters. To produce pseudoviruses that contain the luciferase 
gene to infect Cf2 Th/Syn CCR5 cell, we transfected 293T cells with the HIV-1 
packaging plasmid pCMVDP1DenvpA, the firefly luciferase-expressing plasmid 
pHIvec2.luc and the plasmid expressing the HIV-1 Rev protein and the envelope protein. 
The amount of virus particles produced was determined using Alliance HIV-1 p24 
antigen ELISA Kit (Perkin Elmer, Waltham, MA) per product manual. To prepare 
viruses pseudotyped with mutant Env protein, we created mutations by site-directed 
mutagenesis with QuikChange™ Site-Directed Mutagenesis Kit (Stratagene, Santa Clara, 
CA). 
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 Virus infection 
Target cells (10,000 cells per well) were seeded into all wells of a 96-well flat-bottom 
culture plate. Serial 5-fold dilutions for a total of 11 dilutions of stock pseudoviruses with 
comparable level of p24 were added into quadruplicate wells. We added 20 μg/ml 
DEAE-dextran to enhance virus infection. Target cells were then incubated at 37 °C for 
48 h before the measurement of luminescence using Steady-Glo Luciferase assay system 
(Promega, Madison, WI). 
 
293T cell transfection 
Cell–cell fusion was monitored by cell–cell content mixing or cell–cell lipid mixing after 
co-incubation of effector cells (Env-transfected 293T cells) with target cells 
(3T3.CD4.CCR5). To express WT or AA mutant Env protein, we transfected 293T cells 
with Env-expression plasmids using Fugene HD (Roche Diagnostics) at 3:1 ratio (v/w). 
Thirty-six hours after the transfection, 293T cells were detached and stained with gp120-
specific anti-V3 loop antibody 1A3 to determine the expression level. The amounts of 
Env-expressing plasmids were adjusted to yield comparable expression levels of WT Env 
protein and AA mutant Env protein on the surface of 293T cells. 
 
Luciferase reporter assay of cell-to-cell fusion 
To quantitatively analyze Env-mediated cell–cell fusion process, we used TZM-bl cells, 
which contain Tat-responsive reporter genes for firefly luciferase, as target cells. 293T 
cells transfected with Env-expressing plasmids together with Tat-expressing plasmids 
were mixed with TZM-bl cells at 1:1 ratio. Cell mixtures were cultured in 96-well plates 
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 in triplicates with 20,000 cells in each well. At various time points, cultured cells were 
taken out and stored at − 80 °C. After the final collection, cells were lysed and the 
luciferase activity was measured using Steady-Glo Luciferase assay system (Promega). 
 
Cytoplasmic dye transfer assays 
Effector cells were loaded with cytoplasmic dye Calcein-AM at a concentration of 0.5 
μM, and target cells were loaded with cytoplasmic dye CMTMR (Invitrogen, Grand 
Island, NY) at a concentration of 10 μM for 30 min at 37 °C. After washing three times 
with phosphate-buffered saline, we mixed the two cell populations at 1:1 ratio and 
cultured 300,000 cells in a 24-well plate. Images of cells were taken using Nikon eclipse 
Ti fluorescence microscope after co-incubation for 4 h or overnight. 
 
Lipid mixing assays 
The cell–cell lipid mixing was performed similar to the cell–cell content mixing, except 
that effector cells and target cells were stained with lipophilic dyes DiO (Invitrogen) and 
DiI (Invitrogen), respectively, and images were acquired 2 h after co-incubation. Fusion 
defective Env-transfected 293T effector cells were compared as a negative control. All 
experiments were repeated three times, and representative images were shown. 
 
Flow cytometric analysis of efficiency of membrane lipid transfer during fusion 
293T cells transfected with either Env WT or AA mutant-expressing plasmids or empty 
plasmids were stained with lipophilic dye DiO while TZM-bl cells were stained with 
lipophilic dye DiD. We cultured 300,000 of mixed cells at 1:1 ratio in a 24-well plate for 
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 2 h at 37 °C, dissociated with phosphate-buffered saline and 25 mM 
ethylenediaminetetraacetic acid (EDTA), washed and immediately subjected to flow 
cytometric analysis. DiO and DiD double positive population comprises cells with fused 
membrane. The percentage of fused double positive cells were calculated to quantify 
hemifusion efficiency of WT and AA mutant following the subtraction of background 
dye redistribution between empty vector-transfected effector and target cells, and the 
lipid mixing activity for AA mutant was normalized to that of WT in three independent 
experiments, averaged and plotted. 
 
EPR measurements 
EPR power saturation measurements were performed on a Bruker EMX spectrometer 
using a loop-gap resonator. The immersion depths values were calculated by the ratio of 
accessibility value of O2 to 50 mM nickel (II) ethylenediaminediacetic acid. Samples 
were purged by either a stream of air or nitrogen gas. EPR distance measurements were 
performed with a Bruker ELEXSYS E680 spectrometer using two EPR techniques: 
conventional EPR (used for preliminary assessment) and pulsed EPR (sensitive distance 
range, 15–80 Å). Pulsed EPR DEER experiments were carried out using a dead-time-free 
pulse sequence as described previously (29). Conventional EPR and DEER spectra were 
analyzed with a Monte Carlo/Simplex Gaussian convolution method to extract spin–spin 
distance (30). 
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 NMR structure determination 
NMR experiments were performed using Bruker, Agilent spectrometers equipped with 
cryogenic probes operating at 1H frequency between 900 and 600 MHz at 35 °C, using 
typically 1 mM isotopically labeled MPER samples in 90% H2O/10% D2O, pH adjusted 
to 6.6, with 100 mM d38-DPC. NMR structural determination of HxB2-AA mutant was 
carried out at a lower peptide concentration (500 μM) to prevent aggregation. Two-
dimensional and 15N or 13C edited three-dimensional nuclear Overhauser enhancement 
(NOE) spectroscopy data sets are collected with 60 ms mixing time. RDC data from JNH 
by transverse relaxation optimized spectroscopy experiment, and CAHA (31), JNCO (32) 
and JCOCA (33) by quantitative J experiments were collected using aligned samples 
containing 1 mM MPER and 20 mg/ml DNA nanotube material. Weakly oriented HDO 
with ~ 20 mg/ml DNA yielded 2H quadrupolar splitting of 7–8 Hz in 500 MHz magnet 
field. 
 
NMR data were processed by NMRPipe (34). NMR resonance and NOE assignments 
were completed using CARA (35). NOE distances were calibrated using CYANA (36). 
Backbone dihedral angles restraints are derived from HNHA experiment and chemical-
shift-based TALOS + program (37) that are consistent with local NOE restraints. EPR 
membrane immersion data were adopted after taking into account the maximum length (7 
Å) and dynamics of the nitroxide spin-label used in the EPR experiments. Structure 
models were calculated using Xplor-NIH (38) software with a TENSO module (39) 
incorporating RDC restraints during high-temperature torsion angle dynamics stage and 
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 planeDisPot module (40) incorporating EPR depth restraints during subsequent low-
temperature Cartesian coordinate dynamics stage. 
 
DNA nanotube production 
The modified p7308-bases-long M13mp18 phage DNA was generated at the nanomole 
scale as described previously (41, 42). DNA staple oligonucleotide strands were prepared 
by solid-phase chemical synthesis (Invitrogen) on the 200-nmol scale in salt-free 
purification grade and dried format. Each monomer folding mixture was prepared by 
combining 120 nM phage DNA and 720 nM DNA staple in a pH 8.0 buffer (5 mM Tris 
Cl, 1 mM EDTA, pH 8.0, 20 mM MgCl2), aliquoted into four 96-well plates with 150 μl 
per well (36 ml each monomer). The folding ramp was as follows: 80 °C for 5 min, 
decrease by 1°/5 min to 65 °C and then decrease by 1°/40 min to 20 °C. Each folded 
monomer sample was pooled and purified separately from excess staple strands via 
gravity-flow ion-exchange chromatography (Qiagen-Tip 10000 Column), as described 
previously (17). Nanotube heterodimers were self-assembled by combining purified front 
and rear monomer mixtures together and incubated at 37 °C for 2 h and then precipitated 
by addition of 0.25 volumes of 20% polyethylene glycol 8000 followed by incubation at 
room temperature for 15 min. The nanotubes were recovered by centrifugation at 15,000g 
for 30 min at 4 °C, resuspended in 2.5 mM Tris, 0.5 mM EDTA (pH 8.0) and 10 mM 
MgCl2, then concentrated to 30 mg/ml and buffer-exchanged into desired protein buffer 
(90% H2O/10% D2O, 5 mM MgCl2, 5 mM NaPO4, pH 6.6) with Centricon-100. Finally, 
260 μl of 20 mg/ml nanotubes was mixed with 260 μl of 1 mM 15N/13C-labeled MPER 
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 sample containing 100 mM d38-DPC and 50 mM NaCl before concentrated down to 260 
μl using a Centricon-3 concentrator. 
 
Accession numbers 
The structure coordinates and NMR restraints have been deposited with Protein Data 
Bank (PDB ID: 2ME1, 2ME2, 2ME3, 2ME4) and Biological Magnetic Resonance Bank 
(BMRB ID: 19515, 19513, 19514, 19515) databases. 
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 Chapter 3: Characterization of nanovaccine-elicited anti-MPER 
antibodies via high-throughput microengraving methodologies coupled 
to DNA sequencing and antibody rescue: single plasma cell repertoire 
analysis 
  
 
 
 Introduction 
Despite 30 years of extensive research on HIV-1, AIDS still plagues the world as one 
serious health problem while an effective preventive HIV-1 vaccine remains elusive(2-6). 
The incredible difficulty in developing an HIV-1 vaccine results from multiple 
mechanisms employed by HIV-1 to evade the immune system, such as extensive genetic 
variation of HIV-1 genomes among clades, strains and quasispecies (7, 8), early and rapid 
establishment of viral reservoirs through viral latency (9-12), and direct killing of CD4+ T 
cells, the very lymphocytes normally to orchestrate development of a sterilizing 
immunity against invading pathogens (13). An effective HIV-1 vaccine must target the 
conserved region of HIV-1 viral proteins to prevent viral escape and to block HIV-1 entry 
into target cells with subsequent establishment of viral reservoirs.  
 
The MPER of Env protein is a highly-conserved hydrophobic segment, which plays an 
essential role in Env-mediated virus entry into its target cell (14). Four broadly 
neutralizing antibodies isolated from HIV-infected patients, 2F5, 4E10, Z13e1, and 10E8, 
target the adjacent linear epitopes within this region (15-17). Unfortunately, attempts to 
elicit such broadly neutralizing antibodies using the trimeric gp140 or the gp41 expressed 
on the virus-like particles has been largely unsuccessful due to the immunodominance of 
non-neutralizing epitopes located elsewhere in Env (18-21).  To preclude the antibody 
responses against those non-neutralizing epitopes and to exactly mimic the conformation 
of the antibody-bound conformation, the structurally-defined 4E10 epitope was grafted 
onto a scaffold protein using computational design by others (22). The failure of these 
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 epitope-scaffolds to elicit 4E10-like neutralizing antibodies, despite presenting the MPER 
region in a 4E10-bound state with high structural fidelity suggests that other factors, in 
addition to the epitope conformation, determine the immunogenicity (23). Similarly, 2F5 
epitope-scaffolds elicited antibodies that mimic 2F5 structure-specific recognition of the 
MPER segment without neutralizing activities (24). One notable difference between the 
antibodies such as 11f10 derived from this epitope-scaffold immunization and 2F5 is that 
the former lack the long CDRH3 loop, whose tip was shown to be important for 
neutralizing activities without making direct contacts with the MPER segment (25). It 
was further shown that the CDRH3 loop is indispensible for 2F5 extraction of the lipid-
buried core residues in the MPER whereas interaction of the CDRH3 loop with lipid in 
the absence of MPER binding is negligible (26). Therefore, in this study, we arrayed the 
MPER peptide on the surface of liposome to provide the membrane context and preserve 
the appropriate conformation of MPER for elicitation of 2F5/4E10-like neutralizing 
antibodies. A palmitic acid adduct was placed at the MPER N-terminus to facilitate 
attachment of the MPER to the liposome lipid bilayer. 
 
To analyze whether 2F5/4E10-like broadly neutralizing antibodies are elicited in our 
immunization with N-Palm-MPER/liposomes, we characterized the post-immunization 
sera as well as the elicited monoclonal antibodies (mAb) since such antibodies may be 
too rare to manifest the broadly neutralizing activities in the bulk polyclonal sera. 
Microengraving, which analyzes microarrays containing the secreted products of single 
cells derived from individual wells, is a rapid and efficient method to discover antigen-
specific single B cells by directly analyzing the secreted products (27-29). We combined 
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 this high-throughput screening system with single B cell PCR technology to generate 
MPER-specific mAbs for the fine dissection of the immunogenicity of the N-Palm-
MPER/liposomes.  
 
Results 
Induction of MPER-specific antibodies after MPER /liposome immunization  
To mimic the viral membrane context, the MPER peptide was arrayed on the surface of 
liposomes composed of DOPC and DOPG lipids, with a palmitic acid anchor attached to 
the N-terminus of the MPER. Monophosphoryl lipid A, which is derived from LPS and 
stimulates Toll-like receptor 4 (TLR 4), was used as an adjuvant (30) to stimulate the 
innate immune system. The I-Ad-restricted CD4 helper epitope derived from the parasite 
Leishmania homologue of mammalian RACK1 (LACK) antigen (31, 32) was also 
incorporated in the liposome for the stimulation of CD4+ helper T cells (Figure 3.1A). 
BALB/c mice were immunized with the N-Palm-MPER/liposomes, and then boosted 
with the same immunogens twice at 3-week interval (Figure 3.1B). To test the MPER 
specificity of the post-immunization sera, N-Palm-MPER/liposomes containing DSPE-
PEG (2000) Biotin (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[biotinyl(polyethylene glycol)-2000]) were used as the capture molecule on streptavidin 
plates in the ELISA assay. As shown, MPER specificities were detected in the sera from 
mice immunized with N-Palm-MPER/liposomes with end-point antibody titer of around 
10,000, but were not detected in the sera from the gp120 immunization (Figure 3.1C). 
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Figure 3.1. MPER-specific antibody responses in mice immunized with N-Palm-
MPER/liposomes. A. Illustration of MPER/liposome immunogens. B. Immunization strategy of 
BALB/c mice with N-Palm-MPER/liposomes. C. MPER-specific IgG responses detected with N-
Palm-MPER/liposome ELISA. N-Palm-MPER/liposomes containing DSPE-PEG(2000) biotin on 
streptavidin-coated microplates was used as the capture molecule. Sera were diluted serially. One 
mouse immunized with the irrelevant immunogen (gp120) was used as a negative control. 
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 Optimization of Microengraving to detect MPER-specific antibodies 
To dissect the antibody responses induced by N-Palm-MPER/liposomes, we directly 
measured the antibody production from single cells using a microengraving platform (27). 
Briefly, single cells were loaded onto an array which contains 84, 672 microwells and 
were cultured together with a slide coated with probes. Antibodies secreted from single 
cells were captured by probes on the slides in a process termed printing (Figure 3.2A). 
After interrogation of the slide to detect MPER-specific antibodies, the corresponding 
cells were retrieved for further analysis. In our experiments, N-Palm-MPER/liposomes 
were coated onto the poly-L-lysine glass slide through the interaction between the 
positively-charged poly-L-lysine and the negatively charged DOPG lipid. The coated N-
Palm-MPER/liposomes served as baits to capture antibodies secreted from MPER-
specific plasma cells. For image analysis, the slide was also coated with anti-human IL-6 
antibodies and human IL-6 was added into the printing media to produce a signal in every 
well of the array (Figure 3.2B). As a positive control in establishing this system, cells 
from a previously isolated MPER-specific hybridoma termed M1 (23) were loaded onto 
the array to occupy a fraction of wells as a surrogate for MPER-specific plasma cells. As 
shown in Figure 3.3A, MPER-specific signals were detected in some wells when stained 
with Alexa 647 conjugated anti-mouse IgG while IL-6 signals were detected in all wells 
when stained with Alexa 488 conjugated anti-IL-6 antibodies. The existence of IL-6 
signals in every well in the array permitted the grid alignment to define the positions of 
the MPER-specific signals. As shown in Figure 3.3B, there is no leaking of signals from 
the Alexa 488 channel into the Alexa 647 channel. In the absence of MPER-specific 
antibody-producing cells, no signals were observed. Furthermore, no cross-reactivity  
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Figure 3.2. Outline of a microengraving strategy to detect antigen-specific antibody-secreting 
cells. A. Diagram of the microengraving method. B. Interrogation of slides after printing. Slides 
were coated with N-Palm-MPER/liposomes as well as anti-IL-6 antibodies. MPER-specific 
antibodies captured onto N-Palm-MPER/liposomes were detected with Alexa 647 anti-mouse 
IgG. Human IL-6 was added into the printing media. Human IL-6 was detected with Alexa 488 
anti-human IL-6 to produce signals in every well for grid alignment and localization of MPER-
specific signals. 
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Figure 3.3. Establishment of the microengraving system using the MPER-specific hybridoma 
cells M1. A. Detection and localization of MPER-specific signals. MPER-specific hybridoma 
cells M1 in human IL-6-containing cell culture media (hybridoma cell M1 + human IL-6) were 
loaded onto a fraction of microwells in the array. Both Alexa 647 anti-mouse IgG and Alexa 488 
anti-human IL-6 were added as detection antibodies. MPER-specific signals were detected in 
Alexa 647 channel (left). The absence of signals due to lack of cells in some wells indicated that 
there were no cross-reactivity between human IL-6 and Alexa 647-anti-mouse IgG.  IL-6 signals 
were detected in all wells in Alexa 488 channel for block and feature alignment (middle). The 
positions of the MPER-specific signals were identified after aligning the features with IL-6 
signals (right). B. No spillover of IL-6 signals from Alexa 488 channel into Alexa 647 channel. 
Cell culture media containing human IL-6 were loaded onto the microwells of the array.  Alexa 
488 anti-human IL-6 antibodies were used to detect captured IL-6 molecules. IL-6 signals were 
detected in Alexa 488 channel and no signals were detected in Alexa 647 channel. C. Hybridoma 
cells M1 in cell culture media without IL-6 were loaded onto the microwells in the array. Alexa 
488 anti-human IL-6 antibodies were added as detection antibodies. No signals were detected in 
Alexa 647 channel or Alexa 488 channel. 
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 between MPER-specific antibodies and Alexa 488 anti-IL-6 antibodies was detected 
(Figure 3.3C).  
 
Detection of MPER-specific memory B cells secreting IgM or IgG 
Memory B cells and long-lived plasma cells are responsible for the humoral memory that 
affords protection against incoming pathogens after preventive vaccination (33). To 
characterize humoral memory at the single-cell level, both memory B cells from spleen 
and long-lived plasma cells from bone marrow were analyzed using microengraving.  For 
in vitro memory B cell proliferation and differentiation into antibody secreting cells 
(ASC), memory B cells were sorted after gating live, singlet B cells upon removal of 
naïve B cells (IgD+) and germinal center B cells (GL7+) from total B cells (B220+CD38+)  
3 weeks after the final immunization with N-Palm-MPER/liposomes (Figure 3.4A). LPS 
(TLR4 agonist), Pokeweed mitogen mitogen (a lectin derived from Phytolacca 
americana), ant-mouse IgM  F(ab')2 fragments, and dextran sulfate (DxS), a polyanionic 
derivative of dextran, were tested for their stimulatory activities on B cells to differentiate 
into plasmablasts or plasma cells at day 3, day 4, and day 5 (Figure 3.4B). Among all the 
tested reagents, LPS alone or LPS combined with dextran sulfate yielded the highest 
stimulating activities. After stimulating with LPS (20 µg/ml) or LPS (10 µg/ml) plus 
dextran sulfate (1µg/ml) in vitro for 4 days, around 35% of cells were ASCs, including 
plasmablasts (B220+CD138+) or plasma cells (B220-CD138+) based on FACS analysis.  
We observed the lower percentage of ASC at day 5, presumable due to the increased 
death of the differentiated cells in vitro (34). Anti-mouse IgM F(ab')2 fragments or 
pokeweed mitogen (PWM) had little effect on memory B cells. PWM even inhibited  
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Figure 3.4. Purification and stimulation of memory B cells. A. Memory B cells sorting strategy. 
Memory B cells were sorted from singlet splenocytes stained negative for propidium iodide, 
positive for B220 and CD38, and negative for IgD and GL7. B. In vitro stimulation of B cells. B 
cells purified from spleen were stimulated with LPS, anti-IgM F(ab)2’, pokeweed mitogen, 
dextran sulfate plus LPS, pokeweed mitogen plus LPS for 3 days, 4 days, and 5 days. Cells were 
stained with B200 and CD138 antibodies to check the percentage of antibody secreting cells 
(B200+CD138+ or B220-CD138+). Results from a representative FACS experiment were shown 
here.  
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Figure 3.5. Detection of MPER-specific memory B cells. A. Schematics to show detection of IgG 
and IgM with IgG-specific or IgM-specific secondary antibodies in microengraving. B. A 
representative view of a small area in the scanned image to show positive signals. C. Detection of 
MPER-specific memory B cells secreting IgM or IgG after LPS stimulation in vitro. Y axis 
indicates the median signal intensity of individual wells. X axis indicates the median background 
intensity for individual wells. Also, wells without signals (negative wells) were selected randomly 
over the whole image to show the overall background of the image. 
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 the stimulatory effect of LPS when combined together. Therefore, in the following 
studies, LPS (20 µg/ml) was used to stimulate memory B cells to differentiate into ASCs. 
Sorted memory B cells were stimulated with LPS for 4 days before loading onto the array 
for detection with Alexa 647 anti-mouse IgG and Alexa 594 anti-mouse IgM (Figure 
3.5A). Figure 3.5B shows a representative section from the scanned image, containing the 
MPER-specific signals. 668 signals representing secreted MPER-specific IgM were 
detected from 100, 000 stimulated B cells (0.67%), whereas only 18 signals representing 
secreted MPER-specific IgG were detected (0.02%) (Figure 3.5C). The low frequency of 
IgG-secreting memory B cells could be due to the paucity of class-switched IgG memory 
B cells and/or the preferential stimulation of IgM+ memory B cells by LPS (35, 36).  
 
Detection and isolation of MPER-specific bone marrow plasma cells  
We next checked the long-lived plasma cells, the majority of which reside in the bone 
marrow and are the major source of serum antibodies. To enrich plasma cells from total 
bone marrow cells, CD138+ plasma cells were purified from one mouse 7 days after the 
final immunization with N-Palm-MPER/liposomes. 2,674 signals were detected from 
70,000 purified plasma cells loaded onto one array (Figure 3.6). The signal intensity, 
reflecting the combined effect of the antibody secreting rate and the affinity of the 
antibody,  varied greatly from less than 5000 (646 signals), 5000-10,000 (359 signals), 
10,000-20,000 (770 signals), 20,000-30,000 (512 signals), 30,000-40,000 (262 signals), 
to more than 40,000 (125 signals). In contrast, only 11 signals with signal intensities less 
than 5000 were detected from the unimmunized mouse, confirming the specificity of  
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Figure 3.6. Detection of MPER-specific plasma cells from bone marrow. Plasma cells were 
isolated from bone marrow by depleting B220+ cells and CD49b+ cells and then enriching 
CD138+ cells. 2674 MPER-specific signals were detected from 70, 000 bone marrow plasma cells 
isolated from one mouse immunized with N-palm-MPER/liposomes, whereas only 11 signals 
with signal intensity lower than 5000 were detected from an unimmunized mouse. 
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 this screening platform. The frequency of MPER-specific plasma cells among total bone 
marrow plasma cells is around 3.8%. 
 
Bioinformatics analysis of MPER-specific antibody sequences  
147 single MPER-specific bone marrow plasma cells were retrieved. Figure 3.7A shows 
amplications of Ig gene variable regions from 16 single plasma cells. Heavy chain and 
light chain variable regions were amplified from 38 of these retrieved single plasma cells 
using single cell PCR. The low amplification frequency (26%) suggests that the primers 
used in this study (37) should be further optimized for the amplification of Ig genes from 
BALB/c mice. The sequences of the variable regions were analyzed using IMGT/V-quest 
(38, 39) to identify the closest germline V gene segment. The heavy chains of these 
MPER-specific antibodies were derived from V1, V5 and V8 families and the kappa 
chains of these antibodies were derived from V4, V5, V6 and V17 families (Table 3.1). 
Among the 38 cells with amplified heavy chains and light chains, 7 cells secreted 
antibodies derived from the germline gene segment IGHV1-7/IGKV17-121 and 6 cells 
secreted antibodies derived from the germline gene segment IGHV1-7/IGKV6-15. As 
shown in Figure 3.7B, the CDR3 (complementarity determining region 3) length of the 
heavy chains generally varied in a range of 8-13 amino acids, with the majority (25) of 
the heavy chains containing 8 amino acids. Of note, however, one antibody contained an 
extremely long CDRH3 (18 amino acids). The sequences derived from IgKV17-121 and 
IgKV4-70 germline gene segments and one sequence derived from IgHV5-2 were 
unproductive based on IMGT/V-quest analysis, suggesting that these sequences were 
amplified due to the existence of residual RNA from unproductive recombination during  
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Figure 3.7. Amplification of Ig gene variable region from single plasma cells and analysis of 
CDRH3 length of the amplified sequences. A. Antibody variable regions of heavy chain and light 
chain genes were amplified from single plasma cells. The amplification products from heavy 
chain PCR (around 500 bp) and light chain PCR (around 355 bp) from 16 single plasma cells 
were shown. B. The distribution of the CDRH3 length of amplified sequences from single plasma 
cells. 
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 Table 3.1. The germline gene segment usage of amplified Ig gene variable regions from single 
plasma cells. 
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 Table 3.2. List of antibodies expressed in free-style 293F cells  
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Ab ID. VH-gene VK-gene CDRH3 length CDRL3 length Signal Intensity
5 IGHV1-7 IGKV5-48 8 9 430
26 IGHV5-12-2 IGKV5-48 11 9 5089
58 IGHV5-9-4 IGKV5-43 13 9 568
96 IGHV8-11 IGKV4-53 18 9 1293
113 IGH5-12-1 IGKV5-48 11 9 6738
124 IGHV1-7 IGKV6-15 8 9 9844
146 IGHV1-7 IGKV6-15 8 9 837
 Table 3.3. ELISA analysis of the supernatant of 293F cells transfected with Ab113-expression 
vectors.  
 
 
 
Note: Supernatant from 293F cells transfected with Ab113-expressing vectors or supernatant from 
untransfected 293F cells were diluted at 1:10, 1:100, 1:1000, and 1:10,000 ratio. 10E8 antibodies were used 
a positive control at a serial concentrations of 1, 0.1, 0.001, and 0.001 µg/ml. 
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Ab113 Sup from 293F 10E8
1:10 3.433 0.050 3.374 1 ug/ml
1:100 3.425 0.063 3.381 0.1 ug/ml
1:1000 3.443 0.059 2.396 0.01 ug/ml
1:10,000 3.404 0.074 0.528 0.001 ug/ml
 affinity maturation process. We postulated that those productive sequences from the same 
cells responsible for antibody secretion were missed due to the primers used in the PCR 
reaction for their cloning. 
 
Expression and characterization of MPER-specific recombinant antibodies  
We next cloned the antibody variable region into the expression vectors expressing the 
constant regions from the human IgG1 or kappa chain respectively. MAb with different 
germline gene usage and variable CDRH3 length were selected for the expression in free-
style 293F cells (Table 3.2). We also expressed two monoclonal antibodies mAb 124 and 
mAb 146, which used the same germline gene segments with different signal intensities 
displayed by the corresponding plasma cells in the microengraving assay (Figure 3.5A). 
The supernatants from the cells transfected with antibody expression vectors were tested 
for the MPER specificity by ELISA using biotin-MPER as the capture molecule (Table 
3.3).  Once the MPER-specificity of the cell culture supernatant was confirmed with 
ELISA, the recombinant mAbs were purified with protein G. It was shown previously 
that the polyclonal antibodies elicited with N-Palm-MPER/liposomes targeted a region at 
the C-terminus of the MPER including the amide group (23). Therefore, we tested the 
recombinant antibodies for their binding to the MPER with the amide group at the C-
terminus (MPER-NH2) as well as to the MPER with the carboxyl group at the C-terminus 
(MPER-COOH). As shown by surface plasmon resonance (SPR), all the tested 
recombinant mAbs demonstrated the MPER reactivity, with mAb 58 showing the highest 
binding and mAb 26 showing the weakest binding (Figure 3.8A). Similar to the  
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Figure 3.8. Analysis of monoclonal antibody binding to N-Palm-MPER/liposome or empty 
liposome. A. SPR analysis of recombinant monoclonal antibodies binding to the MPER with the 
amide group on the C-terminus (MPER-NH2) on liposomes (left panel) and  the MPER with 
carboxyl group on the C-terminus (MPER-COOH) on liposomes (right panel). Note that the Y 
axis scale is identical in both panels. B. SPR analysis of recombinant monoclonal antibodies 
binding to DOPC/DOPG liposomes without the MPER peptide. One irrelevant gp120-specific 
mAb 1A3 without lipid reactivity was also shown as a negative control. Response unit scale 
differs in B versus A panels.  
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 polyclonal antibodies purified from the immunized sera, the recombinant mAbs also 
recognized the amide group as changing the amide group to the carboxyl group 
significantly reduced the antibody binding (Figure 3.8A). One important feature of the 
MPER-specific broadly neutralizing antibodies is their lipid reactivity mediated by the 
long CDRH3 loop. Therefore, we also tested the antibody binding to the liposomes 
without the MPER peptide. The antibodies induced in our immunization with N-Palm-
MPER/liposomes showed weak binding to the lipid with fast equilibrium plateau during 
association phase and fast return to baseline during dissociation phase (Figure 3.8B).  
 
The epitope specificity of these recombinant mAbs were further characterized using 
single residue MPER alanine-scanning mutagenesis combined with BIAcore analysis. 
The polyclonal antibodies and the recombinant mAbs shared two key epitope specificities, 
W680 and the amide group at the c-terminal end of the peptide (Figure 3.9A). W680A 
mutation reduced the binding of mAb 58 and polyclonal antibodies to less than 10%, and 
the substitution of the amide group with the carboxyl group also significantly diminished 
the binding of mAb 58 (20%) and polyclonal antibodies (10%).  Despite the similarity in 
binding to W680 and the amide group at the C-terminus, mAb 58 demonstrated more 
extensive contacts with the MPER than the polyclonal antibodies. For example, N677A 
mutation reduced the binding of mAb 58 to less than 10% whereas its effects on 
polyclonal antibodies are modest (58%). Similarly, S668A, N674A as well as I675A 
mutations have stronger effects on mAb 58 binding than on polyclonal antibodies binding. 
We further compared the epitope specificities of three monoclonal antibodies mAb 58, 5 
and113, with different combinations of heavy chain and kappa chain germline gene  
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Figure 3.9 Recombinant monoclonal antibodies displayed similar epitope specificities despite of 
sequence variabilities. A. Epitope analysis of mAb 58 and the polyclonal antibodies purified from 
the immune sera after immunization with N-Palm-MPER/liposomes. B. Comparison of epitope 
specificities of mAbs 5, 58, and 113. C. Heavy chain and kappa chain sequence analysis of 
recombinant monoclonal antibody 5, 58 and 113. 
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 segments. All the three mAbs showed similar binding to S668, W680 and the amide 
group at the N-terminus whereas the binding to other residues are different among the 
three mAbs. N671A mutation actually increased the binding of mAb 5 whereas it did not  
significantly affect mAbs 58 and 113. The effects of F673A mutation are also different, 
which largely retained the binding of mAb 58 (75%) while reduced the binding of mAbs 
5 and 113 by half. N677A mutation also revealed differential effects on the binding of the 
three mAbs with the most dramatic reduction in mAb 58 binding (6%) and the least effect 
on mAb 5 binding (52%). Comparison of amino acid sequences of these three mAbs 
showed that the amino acid sequences in the heavy chain variable regions were quite 
different among the three mAbs, particularly with respect to CDRH3 amino acid 
sequence as well as its length despite similarities in the kappa chain sequences (Figure 
3.9C). 
 
Discussion 
Bone marrow plasma cells secret antibodies to circulate in the blood and other body 
fluids, thereby providing a key line of defense against pathogens. The information on 
antibodies generated by these plasma cells after infection or vaccination, however, has 
been quite scarce. Traditionally, hybridoma technology has been widely used to generate 
mAbs from B cells, although the efficiency is quite low and it usually takes several 
months to get a limited number of mAbs (40). Furthermore, the bone marrow plasma cell 
compartment has been resistant to hybridoma fusion, thereby rendering it impossible to 
analyze bone marrow plasma cells using hybridoma technology (40). Our strategy rapidly 
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 identified the antigen-specific bone marrow plasma cells by directly measuring the 
specificity of antibodies secreted from bone marrow plasma cells. The plasma cells could 
then be retrieved and individual recombinant mAbs rescued by single-cell PCR and 
expression cloning. Therefore our strategy using microengraving offers an efficient way 
to explore the long-lived bone marrow plasma cell compartment at single B cell level and 
to characterize antigen specificity of elicited antibodies as a function of immunogenicity 
as well as B cell repertoire analysis. 
 
Our studies dissect the vaccination-induced humoral responses at the cellular level by 
identification and isolation of MPER-specific bone marrow plasma cells. Our studies 
showed that the recombinant mAbs derived from the bone marrow plasma cells 
recapitulate the sera activities by comparing the epitope specificity of recombinant 
antibodies with that of the sera polyclonal antibodies from the immunized mice (Figure 
3.9).These results are consistent with previous reports that bone marrow plasma cells are 
the major source of sera antibodies (41-44). While all mAbs characterized in this study 
shared two critical residues W680 and the C-terminal amide group with polyclonal 
antibodies derived from immune sera for binding, more residues in the MPER are in 
extensive contact with mAbs, significantly contributing to the binding energy than that of 
polyclonal antibodies in immune sera.  The differences in fine specificity between mAbs 
and the polyclonal antibodies suggest further analysis of other types of antibodies yet to 
be screened in future, although the frequency of B cells producing those types of 
antibodies would presumably be low. 
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 Although mAbs 5, 58, and 113 did not utilize the same germline gene segments and their 
CDRH3 loops are also different in terms of amino acid compositions and lengths, their 
overall epitope specificities are strikingly similar. W680A mutation and substitute of the 
amide adduct to the carboxyl group at the C-terminus showed almost identical effects on 
the binding of these three recombinant mAbs to the MPER. This finding suggests that the 
three different mAbs may recognize the MPER in a similar fashion. Indeed, it was shown 
that VRC01-like antibodies from different donors displayed similar recognition of the 
gp120 CD4-binding site despite significant antibody sequence variability (45). Therefore, 
it is possible that all these three antibodies identify the immunodominant MPER-
recognition motif in the N-Palm-MPER/liposomes despite having different amino acid 
sequences in the respective antigen-binding sites.  
 
It has shown that the antibody repertoire after infections differs among different mouse 
strains (46, 47). The primers used in our studies were designed for repertoire analysis of 
C57BL/6 mice and were estimated to recover around 70% of functionally expressed 
C57BL/6 VH and Vκ genes (37). Therefore, it is not surprising to observe that both 
heavy chain and kappa chain variable regions were amplified from only about 1/3 of 
single B cells retrieved from microengraving. We detected two non-productive V-gene 
segments (IgKV17-121 and IgKV4-70) of kappa chain according to IMGT/V-quest 
analysis from retrieved B cells. Indeed, there are several reports showing that both 
productive and non-productive antibody transcripts exist in different stages of B cell 
development (47-49). Therefore, the non-productive RNA could be the residual RNA of 
non-productive recombination or somatic hypermutation from B cells, whereas the 
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 productive recombinant kappa chains, which formed functional antibodies and produced 
signals in microengraving, were not amplified.  
 
CDRH3 is often a major determinant of the antibody specificity and affinity (50, 51) and 
it has been shown that the long CDRH3 loop plays a significant role in the neutralizing 
activities of MPER-targeting broadly neutralizing antibodies such as 2F5 (26, 52). It was 
revealed that the CDRH3 length from human antibodies vary extensively with the 
average length of about 13 amino acids, whereas the CDRH3 from mouse antibodies are 
more restricted and much shorter, with the average length of about 9 amino acids (53). 
Therefore, there is a genuine concern whether mice could make 2F5 or 4E10-like 
antibodies with long CDRH3 loops and whether the inability to recapitulate the 
neutralizing activities of 2F5 or 4E10 by immunization in mice results from the 
incapability of mice to produce antibodies with long CDRH3 loops. In this study, we 
analyzed the CDRH3 length of all the sequences we amplified from single B cells. 
Although the majority of these antibodies had short CDRH3 loops (8-13 amino acids), 
one antibody mAb 96 did contain the unusually long CDRH3 loops (18 amino acids).  
Expression of mAb 96 is low and requires further optimization for analysis. But future 
studies as to its specificity and lipid binding will be of interest. Regardless, our study 
clearly demonstrated that mice were capable of making antibodies with long CDRH3 
loops, suggesting that the previous failure to elicit 2F5/4E10-like neutralizing antibodies 
is not singularly due to the choice of animals used in immunizations. 
 
104 
 
 Although quite a few of broadly neutralizing antibodies have been isolated from patients 
(54, 55) and these broadly neutralizing antibodies have been shown to be protective in 
rhesus macaques (56, 57), such antibodies have not been elicited through vaccination. 
The antibodies induced in our immunization studies targeted the hinge region and the C-
terminal end of the MPER, which overlap the epitope of the broadly neutralizing 
antibodies 10E8 (17). However these antibodies are unlikely to be neutralizing because 
the antibodies targeted the artificial amide group at the C-terminus of the synthetic 
MPER peptide appended to prevent in vivo proteolysis. It was demonstrated that the 
exposed W680 at the C-terminal end of the MPER is a dominant factor as “hot spot” 
focusing the antibody responses toward the C-terminal region (23). The amide 
recognition and dominance in the antibody responses may be due to its juxtaposition to 
W680 (23). Therefore, in future studies, the antibody responses targeting the artificial 
amide group at the C-terminus of the MPER peptide need to be abolished by eliminating 
the adducts’ exposure to antibodies. Once this is achieved, those antibodies targeting the 
MPER segment in the context of the whole Env protein will need to approach the Env 
spikes at an angle appropriate to avoid a steric clash with either the gp120 or the 
membrane. The future MPER-based immunogen will need to solve these problems, 
probably by adding some adducts at the N-terminal of the MPER to mimic the spatial 
constraint of the gp120. 
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 Materials and Methods 
Materials and Reagents 
HxB2 MPER peptide (ELDKWASLWNWFNITNWLWYIK) with palmitic acid 
conjugated at the N-terminus (MPER-N-Palm) was synthesized following the standard 
procedures on an ABI 431 Peptide Synthesizer using Fmoc chemistry at Massachusetts 
Institute of Technology (Cambridge, MA). Peptide purification was performed on a 
reverse phase C18 or C5 column using HPLC. Palmitic acid conjugation was carried out 
after peptide synthesis using the standard 2-(1H-benzotriazole-1-yl) 1,1,3,3-
tetramethyluronium activation method (58). Liposome preparations for immunization and 
for antibody binding are detailed below. The expression vectors to express the heavy 
chains and light chains of recombinant mAbs were kindly provided by Dr. Hedda 
Wardemann (The Max Planck Institute for Infection Biology, Germany) (37). 
 
Animals and Immunizations 
BALB/c mice were purchased from Taconic and maintained in the animal resources 
facility under the protocol approved by the Animal Use and Care Committee of Dana 
Farber Cancer Institute. BALB/c mice were immunized with 100 ul of MPER-N-
palm/liposome intradermally at the concentration 20 mg/ml. Mice were boosted twice 
with the same immunogens at 3-week interval. 10 days after each immunization, blood 
were drawn retro-orbitally and placed at 4°C overnight. Sera samples were collected the 
next day after centrifugation at 16.1 X103 g for 5 minutes and stored -20°C until use. The 
IgG fraction was purified as detailed below. 
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 ELISA 
A modified indirect ELISA was used to detect MPER-specificity from immunized sera or 
from the supernant of recombinant mAb expression (23). Briefly, a 96-well plate was 
coated with streptavidin diluted in phosphate-buffered saline (PBS) overnight. The plate 
was then blocked with 1% BSA (bovine serum albumin) /PBS . Biotinylated MPER 
peptide or MPER/liposome containing DSPE-PEG(2000) Biotin was incubated with the 
streptavidin-coated plate for 2 hours at room temperature followed with incubation for 2 
hours at 4°C. After washing three times with 0.1% BSA/PBS, either the immunized sera 
or the cell culture supernant diluted in the blocking buffer (1% BSA/PBS) were added 
into the plate and incubated overnight at 4°C. Next day, horseradish peroxidase (HRP)-
conjugated secondary antibodies were added. After incubation at room temperature for 
one hour, o-phenylenediamine dihydrochloride (OPD) substrate was added and the 
absorbance was measured at 490 nm. 
 
Amplification and sequencing of mouse Ig genes 
The amplification of mouse Ig gene variable region was performed following the protocol 
described by Tiller et al.(37) with some modifications. In summary, cDNA was 
synthesized from single B cells retrieved from microengraving experiments using 
SuperScript® III First-Strand Synthesis System (Invitrogen). The variable regions of 
heavy chain and kappa chain of Ig gene were amplified using semi-nest PCR and nest-
PCR respectively. In the first-round heavy chain and kappa chain PCR, 3 ul of cDNA 
products were used as the template. In the second-round heavy chain and kappa chain 
PCR, 1 ul of the first-round PCR products were used as the template.  For heavy chain 
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 PCR, the annealing temperatures for the first-round PCR and second-round PCR were 
50°C. For kappa chain PCR, the annealing temperatures for the first-round PCR and 
second-round PCR were 47°C. To maximize the amplification efficiency and minimize 
the possibility of the mutations introduced in the PCR process, the Q5® High-Fidelity 
DNA Polymerase (New England Biolad) was used as the DNA polymerase. After gel 
purification, the PCR products were sequenced using the 5’-degenerate primers for the 
heavy chains and the kappa chains (37).  
 
Cloning and expression of recombinant mAbs 
The nucleotide sequences of PCR products were analyzed using the IMGT/V-QUEST to 
identify the closest germline V, D, and J gene segments (38, 39). Then gene-specific 
primers were used to amplify the variable regions of Ig gene with the first-round PCR 
products as the template. The PCR products were either cloned into the mouse antibody 
expression vectors directly or ligated into blunt Topo vectors (Invitrogen, Catalogue 
number K2830-20) first before cloning into the mouse antibody expression vectors. 
Suspension-adapted HEK293 cells (Freestyle™ 293-F cells, Invitrogen, Catalogue 
number R790-07) were used for the expression of recombinant mAbs. One day before 
transfection, 0.7X106 293-F cells were seed in 30 ml of FreeStyle™ 293 Expression 
Medium in 125-ml shake flask. 15 μg of heavy-chain expression vectors and 15 μg of 
kappa-chain expression vectors were co-transfected into the 293-F cells using 
293fectin™ Transfection Reagent (Invitrogen, Catalogue number 12347-019). The 
transfected 293-F cells were continually cultured for 5 days before supernatant collection 
for antibody purification. 
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 Antibody purification 
The supernatant collected from cell culture transfected with recombinant expression 
vectors was centrifuged and filtered to remove cell debris. The GammaBind Plus 
Sepharose (GE healthcare life sciences, Catalogue number 17-0886-01) was used to 
purify recombinant mAbs from the cleared supernatant. Briefly, 500 µl of packed 
sepharose were prepared in the column after washing with PBS to remove ethanol. The 
supernatant was loaded onto the GammaBind Plus Sepharose beads and passed through 
the column by gravity. The column was washed again with PBS before elution of the 
bound antibodies with the elution buffer (0.5 M acetic acid pH 3.0).  To prevent any 
detrimental effect of the acidic environment on antibody, 1 M Tris-HCl, pH 9.0 was 
added into the eluted fractions immediately for neutralization. The sample conditions of 
eluted antibodies were further adjusted by buffer exchange with PBS using 10,000 Dalton 
Ultra-4 Centrifugal filter Unit (Millipore, Catalogue number UFC801008).  
 
Bone marrow plasma cell purification 
7 days after the 3rd immunization of N-Palm-MPER/liposome immunogens, one mouse 
was sacrificed using cervical dislocation following CO2 anesthesia. Bone marrow was 
collected from four bones (2 femurs and 2 tibias) by extensively flushing the bone with 
PBS using syringes. Total bone marrow cells were then filtered with 70 µl Nylon cell 
strainer. Bone marrow plasma cells were purified from total bone marrow cells using 
mouse CD138+ plasma cells isolation kit (Miltenyi Biotec, Catalogue number 130-092-
530) following the manufacturer’s manual. In brief, CD49b+ cells and CD45R+ cells were 
depleted by adding biotin-conjugated mAbs against CD49b and CD45R and anti-biotin 
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 microbeads. CD138+ plasma cells were then purified from the remaining cells by add 
microbeads conjugated to monoclonal anti-mouse CD138 antibodies. The purity of 
isolated CD138+ plasma cells were analyzed using flow cytometry after staining with 
anti-CD19 antibodies and anti-CD138 antibodies. 
 
MPER/Liposome preparation for microengraving, ELISA and Surface plasmon 
resonance (SPR) 
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) were mixed with 1,2-di-(9Z-
octadecenoyl)-sn-glycero-3-phospho-(1'-rac-glycerol) (DOPG) in a molar ratio of 1:4. N-
Palm-MPER peptide dissolved in DMSO was added into the lipid mixture in a molar 
ratio of MPER to lipid equal to 1:100. For the microengraving experiment, the molar 
ratio of MPER to lipid is 1:50. The mixture was dried in a glass vial under continuous gas 
streams to form thin lipid films and any residual organic solvents were further removed 
by evaporation under vacuum overnight. The lipid films were rehydrated in phosphate 
buffered saline (pH 7.4) with rigorous vortexing every 10 minutes for one hour. 
Repetitive freeze-thaw cycles combined with liposome extrusion were used to form 
homogenous unilamellar liposome vesicles. The freeze-thaw cycles were repeated six 
times, freezing in liquid nitrogen for 30 seconds followed by thawing at 37°C for 3 
minutes. The liposome extrusion was performed by passing the liposomes through 
polycarbonate membranes (Whatman, Catalogue Number 800309) with 100-nm pores 21 
times. The average size of the liposomes was around 80 nm as determined with a 90Plus 
PALS particle size analyzer (Brookhaven Instruments). 
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 To prepare the liposomes for ELISA, one additional lipid, 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[biotinyl(polyethylene glycol)-2000] (DSPE-PEG(2000) Biotin) 
was added into the lipid mixture in a molar ratio of 1:100. 
 
MPER/Liposome preparation for Immunization 
MPER/liposome immunogens were prepared by mixed the lipids with N-Palm-MPER 
peptide in glass vials as described (23). The molar ratios of lipids and peptide are 
72:18:10:0.4:0.5 for DOPC/DOPG/1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] (PEG2000)/monophosphoryl lipid A (MPLA) and 
MPER-N-palm. The mixture was dried to form thin films after vacuum aspiration 
overnight. A short peptide (SPSLEHPIVVSGSWD) derived from Leishmania major 
LACK1 Antigen was incorporated into the liposomes as CD4 T helper epitopes by 
dissolving the lipid films in 1 mg/ml of LACK1 peptide in PBS. To form homogenous 
liposomes of defined size, the mixture was applied to repetitive freeze-thaw cycles 6 
times and alternative sonication at 12 watts and 3 watts in 30-second intervals for 5 
minutes on ice. After centrifugation using the highest speed in a desktop centrifuge to 
remove any precipitates, the liposome suspensions were passed through polycarbonate 
membranes with a pore size of 0.1 µm to form unilamellar liposome vesicles. 
 
Surface plasmon resonance (SPR) measurements 
For epitope mapping of recombinant mAbs, the binding of each MPER analine mutant 
peptide binding to recombinant mAbs was determined using surface plason resonance 
(SPR) measurement. SPR measurements were performed on a Biacore 3000 system with 
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 the Pioneer L1 sensor chip at 25°C. The sensor chip was first cleaned with 100 µl of 20 
mM CHAPS at a flow rate of 10 µl/min. 30 µl of DOPC/DOPG liposomes (200 µM) 
were immediately injected at a flow rate of 3 µl/min and the liposomes were directly 
attached to the sensor surface. Unbound liposomes or liposomes associated other than 
hydrophobic interactions were removed by washing with sodium hydroxide (20 µl, 20 
mM) at a flow rate of 100 µl/min. BSA (0.1 mg/ml) was injected for 5 minutes to check 
for non-specific binding. Single alanine mutants of MPER peptide were dissolved in the 
running buffer (10 mM HEPES-buffered 150 mM NaCl, HBS-N) and 60 µl of dissolved 
MPER alanine mutant peptide (0.5 µM) was injected at a flow rate of 5 µl/min. Then the 
recombinant mAb solution was applied onto the peptide-liposome complex for 3 min at a 
flow rate of 10 µl/min. The sensor surface was regenerated with a solution of 20 mM 
CHAPS, followed by washing with NaOH (50 mM)/isopropanol (6:4). Each MPER 
alanine mutant peptide was measured for its reactivity with tested mAbs on a freshly 
prepared liposome surface. The amount of each MPER alanine mutant peptide binding to 
the liposome surface was normalized to that of wild-type MPER peptide. A 3-minute 
association period and 3-minute dissociation period were monitored for each MPER 
peptide. The relative binding of MPER mutant peptides to the tested mAbs was 
calculated by dividing the response units for each mutant MPER peptide by the response 
units for wild-type MPER peptide at the 3-min dissociation time point. More than three 
independent experiments were carried out to characterize the epitope specificity of each 
antibodies with different concentrations of peptides or antibodies in each experiment. The 
sensograms were analyzed using BIAevaluation 3.1 sofeware (Biacore).  
 
112 
 
 Microengraving 
MPER-specific plasma cells were detected and isolated using the microengraving 
platform developed in Dr. J. Christopher Love’s lab at MIT (27, 59). Polylysine slides 
were coated with MPER/liposome (50 µg/ml) and anti-IL-6 antibodies (1 µg/ml ) 
(Biolegend, Catalogue number 501102) at 4°C, shaking gently overnight. After 
incubation, the slides were blocked with 3% Non-fat milk dissolved in PBST (phosphate 
buffered saline containing 0.05% Tween-20). The slides were then washed with PBS and 
deionized water sequentially before printing. The microwell arrays were fabricated in 
poly(dimethyl-siloxane) (PDMS) using photolithography and replica molding. The 
microwell arrays were treated with oxygen plasma (PDC-32G, Harrick) for 2 minutes to 
clean the surface and to sterilize the arrays.  
 
The microwell arrays were then blocked with 1% BSA in PBS at room temperature for 1 
hour. Before loading the purified plasma cells, the arrays were rinsed three times with 
600 µl of cell culture media (RPMI supplemented with 10% FBS, penicillin (100 U/ml), 
and streptomycin (100 mg/ml), 2 mM L-glutamine. 50 µM 2-Mercaptoethanol ). Around 
100, 000 cells were loaded onto one array in 300 µl volume. The arrays were washed 
extensively with media containing 0.1 µg/ml of human IL-6 until most cells residing 
outside the microwells in the arrays were removed. The glass slides coated with N-Palm-
MPER/liposomes and anti-IL-6 antibodies and the arrays loaded with cells were 
combined together in a hybridization chamber (DT-1001, Die-Tech) and incubated in 
37°C incubator for one hour. After printing, the slides were removed gently from the 
arrays and blocked in 3% non-fat milk. The arrays containing cells were immersed in cell 
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 culture media and stored at 4°C before retrieving MPER-specific plasma cells. MPER-
specific antibodies secreted from plasma cells and IL-6 in the cell culture media were 
captured onto the slides and were detected respectively with Alexa 647 anti-mouse IgG 
and Alexa 488 anti-IL-6 (Biolegend, Catalogue number 501204). The image was 
analyzed using genepix pro 7 (Molecular Devices). The background intensity for each 
spot was determined using the median value measured in regions around the individual 
spot of the array. The overall background intensity for the entire array was calculated by 
averaging the median intensity values from each channel from at least 100 negative spots. 
The MPER-specific plasma cells were retrieved using a micromanipulator (IM-9A, 
Narishige) ﬁtted with hand-drawn capillaries (GC-1). 
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 Chapter 4: Conclusion and Discussion 
 
 
 
 It was shown clearly in a nonhuman primate challenge model that antibodies to the 
simian immunodeficiency virus (SIV) envelope are necessary and sufficient to prevent 
infection with SIV if these transmitted founder viruses are sensitive to the antibody 
responses (1).  Moreover, passive administration of broadly neutralizing antibodies 
prevents development of disease in challenge studies (2-4). Thus, an effective vaccine 
against HIV-1 should elicit broadly neutralizing antibodies to prevent virus entry and the 
subsequent establishment of latent reservoirs (5, 6). With the development of a high-
throughput strategy to screen B cells either for broadly neutralizing activities directly or 
reactive against structure-based probes corresponding to neutralizing sites in combination 
with efficient recovery of antibody heavy and light chains by PCR, multiple broadly 
neutralizing antibodies have been isolated from HIV-1 infected patients (7-11). These 
broadly neutralizing antibodies together with the previously generated broadly 
neutralizing antibodies using the polyethylene glycol (PEG) electrofusion or 
combinatorial phage display methods (12-15)  reveal 4 different sites of antibody 
recognition on the trimeric Env protein: the CD4 binding site, the V1/V2 region, the 
glycan V3 region, and the MPER which can serve as the targets of vaccine design (16, 
17).  
 
This dissertation focuses on the MPER as the vaccine target for the following reasons. 
First, the MPER sequence is highly conserved (18, 19). Second, the MPER is essential 
for the facile membrane fusion between the virus and the target cell and subsequent virus 
entry (20-24). Last, the MPER contains several overlapping linear epitopes of broadly 
neutralizing antibodies isolated from HIV-1 infected patients, including 2F5, 4E10, 
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 Z13e1 and 10E8 (10, 12). Importantly, MPER-specific antibodies with 10E8-like 
specificities are not rare in HIV-1 infected people (10).  
 
The MPER hinge region provides the conformational flexibility during membrane 
fusion 
The importance of the MPER in Env-mediated membrane fusion and HIV-1 entry has 
been well established by deletion, substitution, and insertion mutations in this region (21, 
24). The membrane-perturbing effect of the MPER was implied to account for its 
essential role in Env-mediated viral fusion (25, 26). This was further corroborated by the 
discovery that MPER-specific broadly neutralizing antibodies 2F5 and 4E10 inhibit 
membrane permeabilization and membrane fusion mediated by the MPER peptide (27, 
28).  Interestingly, Env mutants with the MPER replaced by membrane-perturbing 
peptide indolicidin manifested higher fusion efficiencies than Env mutants with MPER 
replaced by an indolicidin-based alanine analog CP10A (26). CP10A assumes a stable α-
helix conformation due to the presence of alanines. These results suggest that an 
inflexible helical conformation may be detrimental to the role of MPER in the Env-
mediated fusion process. Indeed, NMR analysis of the MPER segment from clade B and 
clade C viruses revealed a common helix-hinge-helix conformation (Figure 2.2b and 
Figure 2.5a) (18). When two amino acids in the hinge region (N671 and D674 in HxB2 
strain) were substituted with alanines, the central hinge region was largely abolished and 
the MPER mutant formed a more deeply lipid-buried and inflexible segment therein 
(Figure 2.5a). The flexibility provided by the central hinge region of the MPER was 
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 important in Env-mediated viral fusion and virus entry, as evidenced by the inefficient 
virus infection of HxB2 and Con089 AA mutant pseudoviruses and the impaired 
membrane fusion mediated by JRFL and ADA Env AA mutants (Figure 2.3 and Figure 
2.4). The basis for the impairment was not due to attenuation of the viral Env trimer 
interaction with CD4 receptors on the target cells since the AA mutation showed similar 
effect on CD4-dependent virus infection as well as CD4-independent virus infection 
(Figure 2.3c). The degree of cleaved Env incorporation into pseudoviruses was similar 
between wild type pseudoviruses and AA mutant pseudoviruses (Figure 2.3).  We 
postulated that the flexible hinge region in the MPER allows membrane approximation of 
the N-helix with three key tryptophan residues. These tryptophans are viral membrane 
disrupting and, in addition, the membrane approximation may foster rotary motion of 
bulky aromatic residues (W672 and F673), thereby disturbing the viral cell membrane 
further (Figure 2.7d). Of note, a helix-hinge-helix motif was observed in some 
antimicrobial peptides with a central flexible hinge region important in membrane 
activities (29-32). For example, removing the central hinge region of the synthetic 
antimicrobial peptide Cecropin A (1-8)-Magainin 2 (1-12) significantly hindered its 
phospholipid vesicle disrupting activity (29). 
 
Characteristics of broadly neutralizing antibodies targeting the MPER 
Consistent with the critical role of the MPER hinge region in Env-mediated membrane 
fusion and HIV entry, MPER-targeting broadly neutralizing antibodies isolated from 
HIV-1 infected individuals block virus entry by abolishing the flexibility imparted by the 
123 
 
 central hinge region (10, 33). For example, Z13e1 straddles the MPER segment and 
freezes the MPER hinge region with broad surface contacts, blocking the conformational 
changes at the membrane interface (33). 4E10 first contacts the surface-exposed residues 
N671and W680, and then extracts the buried residues W672 and F673 out of the 
membrane into its binding pocket (18). Similarly, 2F5 initiates its binding with surface-
exposed residues (E662 to D664) and then extracts the buried residues K665 and W666, 
inducing MPER conformational changes in the N-terminal helix as well as the hinge 
region (18, 33, 34).  
 
These broadly neutralizing antibodies share some unusual features that are essential to 
their neutralizing activities. 2F5 and 4E10 each have utilized long complementarity 
determining region 3 on the heavy chain (CDRH3) to facilitate their binding to 
membrane-embedded epitopes (34-38). These long CDRH3 loops are rigidified through 
hydrogen bonds between the two anti-parallel strands. Most surprisingly, 2F5 CDRH3 
loop also contains 3 prolines, which provide the segmental flexibility together with the N-
terminal glycine residues and allow an appropriate insertion of the CDRH3 loop in the 
membrane (34). The binding of human 2F5 to the MPER in a membrane environment 
was investigated through biophysical methods including NMR, EPR and hydrogen-
deuterium exchange mass spectrometry. It was revealed that MPER recognition by 2F5 is 
mediated by a paratope more extensive than core binding site contacts alone, and in this 
stepwise process, MPER extraction from the viral membrane is accomplished by dynamic 
rearrangement through an apparent scoop-like movement of heavy chain CDRH3 (34). 
Conformational changes in both the MPER and the paratope are necessary for core-
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 epitope recognition on the virus. Therefore, virus neutralization by the MPER-targeted 
antibodies relies heavily on the plasticity of the antibody-combining site. The 
requirement for hydrophobic residues in CDRH3 to mediate viral neutralization and 
binding to the MPER on a viral membrane are reflective of these requirements (35, 37). 
 
Another prominent feature of these broadly neutralizing antibodies is a high degree of 
somatic mutation. For example, the mAb 10E8 isolated from one HIV-1 infected donor 
was found to contain 21% nucleotide mutations in the heavy chain variable regions and 
12% nucleotide mutations in the lamda chain variable regions compared to the unmutated 
germline gene (10). The extensive somatic mutations may result from the prolonged 
antigenic stimulation by continuously evolving viruses in the chronically infected patients. 
A recent study by Haynes et al., for example, documents this concomitant virus evolution 
and antibody maturation using next-generation sequencing of viruses and antibodies from 
a single patient over time. It was shown that the transmitted/founder virus Env could bind 
the ancestory CH101 strongly with extensive viral diversification around the CH101 
epitope driving the development of the CH103 neutralization breadth that follows (39). 
Furthermore, the study by Nussenzweig et al. shows that these broadly neutralizing 
antibodies require somatic mutations in both CDR loops and framework regions, which 
partly explains why these antibodies are usually generated after patients have been 
infected with viruses for several years (40). 
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 Induction of broadly neutralizing antibodies targeting MPER by immunization 
The extraordinary features of these broadly neutralizing antibodies have made it 
extremely difficult to elicit these antibodies through conventional immunization. The 
immune system develops various regulatory mechanisms to disfavor B cells with long 
CDRH3 loops due to the association with autoreactivity or interference with IgH and IgL 
pairing (41, 42). 2F5/4E10 IgH knock-in mice reveal a significant reduction of pro/pre-B 
cells and mature B cells in bone marrow, supporting the notion that, as some have 
suggested, autoreactivity may hinder the elicitation of 2F5/4E10-like antibodies by 
central as well as peripheral tolerance mechanisms (43, 44). Also, these rarely elicited 
broadly neutralizing antibodies in natural HIV-1 infections prefer a small subset of D and 
J gene segments that are suitable for the formation of long CDRH3 loops (45). The 
limited genetic elements used to form long CDRH3 loops among broadly neutralizing 
antibodies further restricts the possibility of inducing such antibodies. Also, there was 
concern that mice usually generate antibodies with shorter CDRH3 loops than human and 
therefore mice are not suitable for the studies of vaccine to elicit broadly neutralizing 
antibodies. 
Despite these challenges, mAbs with long CDRH3 loops were elicited in our studies with 
N-Palm-MPER/liposomes immunization and, importantly, these mAbs demonstrated 
very weak lipid reactivities compared to 4E10. Therefore, our study indicates that it is 
possible to generate 4E10-like broadly neutralizing antibodies with long CDRH3 loops in 
mice with an appropriate immunogen. 
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 The extensive somatic mutations among many broadly neutralizing antibodies represent 
another challenge of inducing such antibodies. It usually takes several years for the 
immune system to accumulate these essential somatic mutations, evidenced by the 
prevalence of these broadly neutralizing antibodies in chronically infected patients rather 
than in elite controllers and viremic controllers (46, 47). Not surprisingly, the germline 
antibodies generated by reverting these somatic mutations fail to engage the same 
epitopes as the somatically mutated mature antibodies, suggesting that the germline 
antibodies may recognize other antigens rather than the targets of these broadly 
neutralizing antibodies whose appearance is late in the course in HIV-1 infection (48, 49). 
These results further complicate the vaccine design as to what immunogens should be 
included to engage B cells expressing these germline antibodies. 
 
Nevertheless, we note that the mutation rate of MPER-specific broadly neutralizing 
antibodies is much lower than that of CD4 binding site-specific broadly neutralizing 
antibodies (50), suggesting that it is more feasible to elicit MPER-specific less-mutated 
antibodies than to elicit CD4 binding site-specific hypermutated antibodies. This low 
mutation rate might be reflective of little immune pressure brought to bear on this 
segment which is largely stealthy, being lipid immersed. Evidence in favor of this notion 
came from guinea pig studies in which guinea pigs were immunized with three doses of 
virus like particles (VLP) or SF9 cells presenting gp41 derivatives. The immune sera 
were found to contain high titered anti-VLP antibodies whereas the specific anti-gp41 
antibody responses were low without neutralizing activities. The absence of the anti-gp41 
antibody responses may result from the low expression level of the gp41 relative to the 
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 many other proteins derived from host cells and incorporated onto the VLP surface. 
Furthermore, the anti-gp41 antibody responses focus on the C-terminal heptad repeat of 
the gp41 and away from the MPER (51). Therefore it was suggested that vaccine design 
targeting the MPER would need to address the complexity of epitope display as well as 
issues of natural immunodominance. 
 
In our studies, the MPER peptide was selected as the immunogen to preclude the 
antibody responses toward the immunodominant non-neutralizing epitopes. The 
antibodies elicited in our studies with the MPER as immunogens are highly mutated (6% 
around the VH region), which is similar to cross-reactive anti-MPER monoclonal 
antibodies M66.6 while less than that of 4E10/10E8. If higher mutation rate is needed for 
broadly neutralizing activities, increasing the mutation rate through heterologous 
immunization with different MPER variants or more boost immunizations should be 
considered. 
 
Recently, epitope-specific strategies have been proposed to elicit the broadly neutralizing 
antibodies targeting the conserved epitopes and thereby avoiding the induction of non-
neutralizing antibodies against the immunodominant epitopes elsewhere in the Env 
protein (52-55). In this regard, 2F5 epitopes were grafted to select scaffolds to mimic its 
2F5-bound conformation. Structural analysis by x-ray crystallography revealed excellent 
mimicry of that bound conformation. The elicited antibodies, although binding to the 
gp41 MPER peptide similar to 2F5, were non-neutralizing. A close examination of the 
mAb 11f10 induced by 2F5 epitope-scaffold uncovered a significant difference between 
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 these two antibodies: 11f10 lacks the corresponding extended tip of the CDRH3 loop in 
2F5. This study further demonstrates the importance of the long CDRH3 loops in 
neutralizing activities of 2F5 (52). Of further note, 11f10 failed to recognize the MPER 
on a lipid membrane. Similarly, the polyclonal sera induced by the scaffold displaying 
4E10 epitopes failed to show broad neutralizing activities (53). The futility of the current 
epitope-specific strategies in eliciting 2F5/4E10-like neutralizing antibodies indicates the 
essential requirement for the membrane context in the generation of these broadly 
neutralizing antibodies. Therefore, in our studies, the MPER peptide was arrayed on the 
liposomes to mimic the membrane environment (Figure 3.1A). 
 
Dissection of antibody responses after immunization with microengraving and 
single cell PCR 
Following the isolation of new potent broadly neutralizing monoclonal antibodies from 
HIV-1 infected individuals and structural determination of these antibodies, the 
antigenicity of the epitopes of these broadly neutralizing antibodies has been well studied. 
The immunogenicity of these epitopes in the native context (the Env protein) or in the 
artificial context (scaffold proteins), however, has been less clear, thereby hindering the 
generation of the broadly neutralizing antibodies through immunization. Also, the 
antibody responses are heterogeneous in terms of the antibody specificities and the 
antibody affinities. In Chapter 3, we developed a high-throughput platform to interrogate 
the memory B cell as well as the plasma cell compartments and evaluate MPER-
specificity at the single-cell level after N-palm-MPER/liposome immunization. We 
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 successfully detected MPER-specific memory B cells and bone marrow plasma cells after 
immunization and recovered the mAbs from bone marrow plasma cells using the single B 
cell PCR technology (56). We identified individual mAb versions of the antibody 
reactivities contained in the bulk IgG of immunized animals with characterization of 
additional details of distinguishing fine specificities. Several VH and VL genes were 
found to create similar antibody specificities.  
 
As identified by earlier studies, the immunogenicity of the membrane-embedded MPER 
segment is dominated by residue accessibility and modulated by stereochemistry (57). 
W680 is the hot spot of antibody recognition, being a fully exposed large hydrophobic 
side chain. As the C-terminus was amidated to prevent proteolysis and located proximal 
to this tryptophan, its specificity is included in the antibody recognition elicited in 
vaccination in these experiments. Hence, while the antibodies analyzed lack sufficient 
reactivity to native MPER to foster neutralizing activity, the use of this screening 
technology offers facile means to judge B cell antibody repertoire generation. 
 
In addition, the selection strategy using the microengraving platform can be further 
modified to focus on selection of 4E10/10E8-like antibodies targeting the central MPER 
hinge region. It has been shown that W672 and F673 are essential for 4E10/10E8 binding 
to the MEPR/liposomes and mutations to alanine at either of these two positions abolish 
the binding of 4E10/10E8. Bsed on this observation, we could screen for 4E10/10E8-like 
broadly neutralizing antiboides by coating slides with anti-mouse antibodies and 
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 interrogating the captured antibodies on slides for binding to wild type MPER liposomes 
but not to MPER liposomes containing mutations at positions 672 and 673. 
 
A path to successful HIV vaccine design 
As described earlier, the MPER is a key target for HIV-1 vaccine design due to its highly 
conserved sequence and essential function in the Env-mediated HIV-1 entry process. 
Furthermore, the existence of broadly neutralizing antibodies targeting this region in 
natural infections suggests the capability of the immune system to generate neutralizing 
antibodies against this membrane-embedded segment. Together, these findings indicate 
that it is feasible to elicit broadly neutralizing antibodies targeting the MPER segment. 
We designed an MPER-targeted immunogen by arraying the N-Palm-MPER peptide on 
the surface of liposomes with the incorporation of T cell help epitope LACK and TLR4 
agonist MPLA. When BALB/c mice were immunized with the N-Palm-MPER/liposomes, 
the immune sera and the polyclonal antibodies derived from the immune sera 
demonstrated MPER-specificity and roughly 4% of long-lived plasma cells in the bone 
marrow were reactive with the MPER. Single B cell analysis of the antibody responses 
elicited with the N-Palm-MPER/liposomes found that a variety of VH and VL sequences 
were utilized to generate mAbs with similar epitope specificities. And importantly, our 
studies showed that it was possible to induce antibodies with long CDRH3 loops in mice 
immunized with N-Palm-MPER/liposomes and these mAbs bound the lipid membrane 
per se very weakly. The elicited antibodies in our studies, however, lack neutralizing 
activities due to their reactivity with the artificial amide group at the N-terminus of the 
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 MPER. As a recent study showed that immunogenicity using lipid arrayed MPER can be 
manipulated via site-directed mutagenesis or structural constraints to modulate surface 
display on liposomes (57), future studies shall remove the amide-directed antibody 
responses by either burying the adduct at the end of the acyl chain inserted into the lipid 
membrane via a polycarbon spacer or, alternatively, by adding a transmembrane segment 
to anchor the MPER region. Finally it remains to be determined as to the fraction of 
elicited antibodies that bind to the liposome-embedded MPER at an acute angle rather 
than normal to the membrane. The former are likely to interact with the native MPER on 
envelope spikes whereas the latter will not. To increase the fraction of antibodies with the 
desired trajectory, future studies need to place steric constraints on the MPER to obviate 
this problem. An alternative would be to enrich the MPER-specific antibodies reactive 
with the native Env through heterologous immunization with MPER liposomes and the 
gp160 containing formulations or, perhaps use MPER liposomes without and with 
ectodomains to focus the antibody elicitation to those with the acute angle approach type. 
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 Abstract 
Broadly neutralizing antibodies such as 2F5 are directed against the membrane-proximal 
external region (MPER) of HIV-1 GP41 and recognize well-defined linear core 
sequences. These epitopes can be engrafted onto protein scaffolds to serve as 
immunogens with high structural fidelity. Although antibodies that bind to this core 
GP41 epitope can be elicited, they lack neutralizing activity. To understand this paradox, 
we used biophysical methods to investigate the binding of human 2F5 to the MPER in a 
membrane environment, where it resides in vivo. Recognition is stepwise, through a 
paratope more extensive than core binding site contacts alone, and dynamic 
rearrangement through an apparent scoop-like movement of heavy chain 
complementarity-determining region 3 (CDRH3) is essential for MPER extraction from 
the viral membrane. Core-epitope recognition on the virus requires the induction of 
conformational changes in both the MPER and the paratope. Hence, target neutralization 
through this lipid-embedded viral segment places stringent requirements on the plasticity 
of the antibody combining site.  
 
A  protective  vaccine  against  HIV-1  requires  the  stimulation  of  a robust immune 
response to elicit broadly neutralizing antibodies (BNAbs) (1). BNAbs are essential to 
prevent viral pathology, generally by inhibiting entry of the retrovirus into host cells, 
thereby blocking viral replication as well as proviral integration into the human genome. 
Integration establishes latent reservoirs of disease (2). The trimeric envelope protein, 
consisting of three protomers of GP120 noncovalently attached to GP41, is the only viral 
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 protein that is exposed on the virion surface. Entry of HIV-1 into human T lymphocytes 
is mediated first by attachment of its envelope GP120 subunit to the cellular receptor 
(CD4), followed by binding to the co-receptor (CCR5 or CXCR4) (3). These interactions 
foster structural rearrangement of the membrane-anchored HIV-1 envelope GP41 subunit, 
subsequently leading to viral fusion with the host cell (4, 5). Therefore, antibody-
mediated protection against HIV-1 must target accessible, functionally relevant and 
conserved spike epitopes. 
 
The development of effective vaccines capable of eliciting BNAbs to HIV-1 has been 
extremely challenging. The failure to create an effective vaccine to control the global 
HIV-1 pandemic is a consequence of the extensive mechanisms exploited by the virus to 
escape protective humoral immunity (6-8). Genetic sequence variability resulting from 
the error-prone HIV-1 reverse transcriptase has led the virus to evolve into many 
subtypes, and multiple quasispecies circulate at any one time in an infected individual. In 
most people infected with HIV-1, antibody-neutralizing activities are strain specific6. 
However, a few chronically infected subjects develop antibodies that are capable of 
neutralizing diverse viral strains (9). Monoclonal antibodies (mAbs)  
that are broadly neutralizing have been isolated from these individuals and characterized 
in an effort to define potential targets for  HIV-1 immunogen design. Among these 
antibodies, several (b12, 2G12, PG9, PG16 and VRC01) recognize conserved regions in 
GP120, whereas others (2F5,  4E10  and  Z13e1) bind to juxtaposed linear epitopes 
within the GP41 MPER (10-16). 
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 The MPER is a highly conserved, tryptophan-rich, hydrophobic segment (residues 662–
683) that is important for viral fusion (17). This region lies at the base of the GP41 
ectodomain, immediately proximal to the transmembrane segment of the protein. 
Structural analysis of the MPER from HIV-1 strain HXB2 suggests that the 2F5 and 
4E10 epitopes are membrane encrypted within an L-shaped MPER on the membrane 
surface (18). The MPER is configured into two helical parts with different membrane 
orientations: a tilted N-terminal segment (residues 664–672) and a nearly flat C-terminal 
helix (residues 675–683) connected to each other through a flexible hinge.  This bipartite 
arrangement is well suited to mediate fusion-related conformational change. In line with 
this observation, biochemical and structural analyses suggest a possible interaction of 2F5 
and 4E10 with phospholipids (11, 19-22). Although in crystal structures there are no 
observed contacts between the tip of the unusually long heavy chain complementarity-
determining region 3 (CDRH3) and the MPER peptide segment, CDRH3 is essential for 
neutralization by both 2F5 and 4E10 antibodies (23-27). Elimination of the tip or of key 
hydrophobic CDRH3 residues abrogates the neutralizing activity of such 2F5 and 4E10 
variants. As a consequence, it has been proposed that BNAbs to MPER associate initially 
with the viral membrane and subsequently capture the MPER in a two-step process (28). 
 
Extensive structural and biochemical information on the BNAb 2F5 and its sequential 
core epitope have guided the design of immunogens to elicit antibodies capable of 
inhibiting viral infection (29).  For example, epitope-engrafted scaffold immunogens 
configure the 2F5 core epitope (ELDKWA) in a manner precisely mimicking that of the 
2F5-bound epitope as verified by X-ray crystallography, but scaffold-elicited antibodies 
141 
 
 such as 11F10 lack detectable neutralizing activity (30). To understand this paradox, we 
conducted NMR, EPR and hydrogen-deuterium exchange (HX)-MS studies to assess the 
manner in which 2F5 binds to the MPER in a membrane environment. Our results show 
that the 2F5 paratope interacts extensively with the MPER segment and surrounding lipid 
in addition to the core epitope. Moreover, 2F5 induces substantial conformational 
changes in the hinge and N-terminal helical segment in a process that fosters the 
extraction of lipid-buried core residues and is dependent on the CDRH3 loop, whose lipid 
interaction per se is negligible in the absence of MPER binding. The rigidification of 
CDRH3 by an internal hydrogen bond network and a proline cluster in conjunction with 
hydrophobic residues at its tip allow the antibody to function as an extraction scoop. In 
addition to explaining why recognition of the core 2F5 epitope is insufficient in itself to 
mediate viral neutralization, our findings suggest that antibody can function as an atomic 
tool to mediate structural rearrangement. These findings extend the concept of antibody 
motion from that required to recognize a single state (that is, an induced fit) to that 
required to recognize two states (a membrane-embedded epitope and an extracted 
epitope). These data offer new insights for MPER-directed BNAb generation. 
 
Results 
The 2F5 CDRH3 tip affects binding to membrane-embedded MPER 
To investigate why an antibody with high affinity for target epitope recognition lacks 
functional antiviral activity, the binding mode of the non-neutralizing mAb 11F10, was 
compared to that of the BNAb 2F5. Consistent with structural studies, binding of 11F10 
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 and 2F5 to an MPER peptide in the absence of lipid was comparable, as measured by 
surface plasmon resonance SPR assay (Figure A.1a). Unexpectedly, 11F10 was incapable 
of interacting with the MPER when the peptide was arrayed on liposomes (Figure A.1b). 
The substantial length of the 2F5 CDRH3 loop (22 residues) and its hydrophobic 
character (Figure A.1c) are thought to be important for mediating membrane interactions 
and 2F5 activity. Notably, 11F10 lacks these characteristics. Furthermore, double serine 
substitution in 2F5 at residues Leu100A and Phe100B of CDRH3 (2F5 L100AS F100BS) 
completely abrogate neutralizing activity, whereas the I100FS and F100BS single 
substitutions reduce potency by approximately two orders of magnitude relative to wild-
type  (WT) 2F5 in half-maximum inhibitory concentration (IC50) viral-neutralization 
assays (27). Although the affinity of the 2F5 L100AS F100BS mutant for the MPER 
peptide in the absence of lipid is not affected by the CDRH3 tip mutations (Figure A.1a), 
consistent with previous findings (27), the binding of 2F5 L100AS F100BS to the MPER 
segment is substantially reduced when configured on an HIV virion-mimic membrane 
surface (Figure A.1b). As shown in Figure 1d and representative sensorgrams (see 
Supplementary Figure 1), the binding equilibrium dissociation constant (Kd) that was 
observed for 2F5 L100AS F100BS (476 nM) was two orders of magnitude lower than that 
observed for WT 2F5 (3.1 nM). 2F5 I100FS bound to the MPER segment less well than 
WT 2F5, with a Kd of 28 nM, and 2F5 F100BS manifested a decrease in Kd to 97 nM. 
 
Concurrent protection of 2F5 CDRH3 and L2 from HX 
Despite the absence of contact between CDRH3 and the MPER peptide in a crystal 
structure (Figure A.1c), the apex of CDRH3 may have an indirect but key functional role  
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Figure A.1.  Binding of 2F5, 2F5 mutant L100AS F100BS and 11F10 to MPER in solution versus 
on a lipid membrane. (a) Antibody binding to the biotin-MPER peptide attached to streptavidin 
on the CM5 surface chip, as assessed by SPR. (b) Antibody binding to the MPER–liposome 
complex (mimicking the HIV virion) attached to L1 chip surface, as assessed by SPR. The 
peptide sequence biotin-GGG-QQEKNEQELLELDKWASLWN was used for the binding 
analysis in solution, and QQEKNEQELLELDKWASLWNWFNI was used for the analysis in a 
membrane environment. (c) Location of mutation residues in the CDRH3 loop (light blue) of 2F5 
in complex with MPER peptide (pink), taken from PDB 1TJI19. Note that in the long CDRH3 
loop, residues between 100 and 101 are numbered with appended letters (100, 100A, 100B and so 
on) by Kabat numbering. Heavy and light chains of 2F5 are indicated by orange and green, 
respectively. (d) SPR binding constants of WT 2F5 and mutant 2F5 variants binding to MPER 
segments on the surface of a DOPC-DOPG membrane linked to an L1 chip. Under our 
experimental conditions, no inverse correlation was seen between dissociation rate and contact 
time21 (ranging from 30 s to 15 min) (see Supplementary Figure 1b,c), so binding data were fit to 
a 1:1 Langmuir model.  
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 in mediating 2F5 binding to its core epitope. To examine this possibility, we used HX-
MS to assess conformational changes (31). After solvent deuterons were exchanged with 
backbone amide hydrogens for various time periods (15 s to 4 h) at rates dependent on 
hydrogen bonding and solvent accessibility, the quenched protein was digested with 
pepsin. Deuterium incorporation into each pepsin fragment was analyzed by electrospray 
MS (32) (over 40 fragments in total; see Supplementary Figure 2). Key peptides and their 
relation to each of the CDRs are shown in Figure A.2a. Exchange into the WT 2F5 Fab 
alone provided baseline data for the protein in solution to be compared with the antibody 
fragment complexed to MPER in the presence and absence of liposomes. The same 
experiments were carried out for the Fab of 2F5 F100BS and 2F5 I100FS, and data were 
compared. As a control, WT 2F5 Fab exchange was also measured in liposomes lacking 
the MPER peptide. For  most  of  peptides  derived  from  the  WT  and  mutant 2F5 Fab 
regions, there was little change in exchange following binding to MPER  embedded  in  
liposomes  (Figure A.2b, top row, and Supplementary Figures 3–5). Likewise, exchange 
into the several CDR regions that contact the MPER in the crystal structure (for example, 
H1 and H2) was not affected differentially by the MPER being in solution or embedded 
in liposomes. Although light chain CDR-3 (CDRL3) also interacts with the MPER, no 
peptides covering CDRL3 could be located in the HX-MS experiments (see 
Supplementary Figure 2). However, there were reproducible differences in exchange for 
CDRH3 and CDRL2 of WT 2F5 Fab (Figure A.2b, left column). The observed 
differences were well outside the error of deuterium-level determination (±0.25 Da). In 
these regions, the amount of deuterium incorporated into 2F5 was lowest in the presence 
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 of MPER embedded in liposomes, indicating that 2F5 is protected from exchange as a 
result of binding to MPER in the liposome. 
 
Hydrogen exchange into the 2F5 F100BS and 2F5 I100FS Fab regions was compared to 
exchange into WT 2F5 Fab (Figure A.2b). Exchange into each of the mutant Fab regions 
was not markedly altered in the absence of MPER, but obvious differences were found 
between WT and mutant Fab regions, when bound to MPER with and without lipid. For 
example, protection from exchange in CDRH3 and CDRL2 as a result of binding MPER 
in solution was reduced in both mutants relative to WT 2F5. The shape of the deuterium 
incorporation lines was also different between WT and mutants, in that MPER-bound 
mutant 2F5 became deuterated faster than WT 2F5. The raw mass spectra indicated that 
these changes were the result of redistribution of the population of multiple 
conformations. 
 
A single 2F5 CDRH3 conformation with lipid-embedded MPER 
In addition to protection from exchange, when 2F5 bound to the MPER in solution, the 
mass spectra indicated that the antibody adopted multiple conformers, in contrast to a 
single conformational population found for unligated 2F5. The regions where multiple 
conformational forms exist cover the C-terminal half (residues Phe100B–Asp101) of 
CDRH3 and the N-terminal portion (residues 46–49) of CDRL2 were identified by 
unique isotopic distributions that are characteristic of multiple peptide conformations. An 
example of the spectra is shown in Figure A.2c for CDRH3 (see also Figure A.3 for 
spectra of L2). Multiple populations distinguished themselves in these experiments by the 
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 appearance of bimodal isotope patterns. These patterns may be due to EX1 kinetics (33, 
34): one population represents a more exposed form of the protein, hence incorporating 
more deuterium to yield a higher mass (Figure A.2c, blue lines), whereas the other 
population is more protected, with less deuterium incorporated and a lower mass 
therefore (Figure A.2c, red lines). These populations interconvert owing to protein 
‘breathing’ or dynamics, but because the deuterium-labeling reaction is unidirectional 
(~95% (v/v) D2O solution), all molecular species eventually reach the higher mass (that is, 
the more deuterated form), and the rate of conversion between the two forms correlates 
with the change in the population distribution. A less protected form was found for 
CDRH3 of unbound 2F5 (2F5 alone), whereas multiple populations were found for 2F5 
bound to soluble MPER (+ MPER only). This suggested that MPER binding slowed the 
2F5 protein dynamics so that more time was required to reach the upper distribution. The 
10-min time point is shown in Figures A.2 and A.3 for purposes of illustration, but the 
distributions were characterized for all time points. In the presence of lipid (+ MPER in 
lipid), there was only one protected form, as evidenced by the single-isotope distribution 
at lower mass (Figure A.2c) and the decreased amount of exchange found in the 
incorporation graphs (Figure A.2b, triangle symbols in the WT Fab column). Therefore, 
MPER embedded in liposomes had the greatest ability to prevent protein breathing and 
dynamics in the WT 2F5 Fab, presumably owing to the influence of the lipids in altering 
the motions in the Fab, particularly in CDRH3 and, to a lesser extent, in CDRL2. In 
contrast to the WT 2F5 Fab, in the CDRH3 and CDRL2 regions of the 2F5 F100BS and 
2F5 I100FS Fab peptides there was no bimodal pattern after 10 min of labeling. Instead, 
an unprotected population resembling the unbound protein was observed (Figure A.3). 
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 There was a bimodal pattern earlier in the time course of exchange, but the conversion 
rate between the protected and unprotected forms was much faster for the mutants than 
for WT 2F5, which is also shown by the rapid increase in the relative deuterium levels in 
the kinetic analysis (Figure A.2b). Maximal deuteration was reached much more quickly 
in the mutants than in WT 2F5, as seen by comparing the line shapes of incorporation 
into CDRH3 and CDRL2 for 2F5 bound to MPER in liposomes (Figure A.2b, triangles). 
By the 10-min time point shown in Figure A.2c, both mutants were heavily deuterated, 
without the protection that was occurring for WT 2F5. Thus, mutation at the tip of the 
CDRH3 loop accelerates deuteration and dynamic conversion between conformations, 
consistent with a destabilized structure and/or the loss of a strong interaction that 
otherwise mediates solvent occlusion. Whereas the WT 2F5 Fab was stabilized by the 
MPER-lipid environment, this was not the case for the mutants. 
 
It was perhaps surprising to observe changes in CDRL2 when WT 2F5 Fab was bound to 
MPER in liposomes, considering that CDRL2 is at a distance from the MPER core 
epitope in the crystal structure. Nevertheless, the HX-MS data clearly indicated that 
CDRL2 was affected by interactions between 2F5 and MPER in liposomes, primarily 
only in WT 2F5 (Figure A.3b). Two overlapping peptides in the HX-MS experiments 
(light chain residues 46–53 and 48–54) allowed us to conclude that the region of CDRL2 
that was most involved in this effect was between residues 46 and 49, because the raw 
spectra of the shorter peptide (residues 48–54) did not have the bimodal kinetic signature 
observed in CDRL2 residues 46–53 and CDRH3 residues 100B–100N (as shown in Figure 
A.3). The hydrophobic segment of CDRL2 (46LLIY49) is not surfaced exposed and, 
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Figure A.2. HX-MS of 2F5 and mutant 2F5 variants. (a) Location of CDR loops shown on the 
crystal structure of 2F5 (PDB 1TJG)19.  The atoms of MPER peptide in the crystal structure are 
shown as yellow balls. Residues Phe100B and Ile100F in CDRH3 are indicated in the inset image, 
which shows the same structure but with the peptides used in b indicated and colored according to 
the key. (b) Representative deuterium exchange curves for important regions of WT 2F5, 2F5 
F100BS and 2F5 I100FS. The residues of each peptide are indicated. The s.d. of each data point is, 
at most, ±0.25 Da. (c) Mass spectra of peptide 100B-FGVPIARGPVNAM-100N from the CDRH3 
after 10 min in deuterated buffer. Idealized distributions in the bimodal pattern are indicated by 
the red (lower mass, more protected) and blue (higher mass, less protected) lines.  
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 hence, is not anticipated to interact with membrane or contribute energetically to peptide 
binding, in contrast to CDRH3 (27). In the crystal structure, residues 46–50 of CDRL2 
are directly across from the C-terminal half of CDRH3, the same region that had altered 
deuterium exchange on binding MPER in liposomes (Figure A.2a,b). One hydrogen bond 
is observed between CDRL2 D50 and CDRH3 N100L. Therefore, conformational change 
in CDRH3 may strengthen the association of CDRH3 with CDRL2 through additional 
hydrogen bonds or other contacts on productive interaction of WT 2F5 with MPER in 
liposomes, affording protection from deuterium exchange for both of these regions. This 
interaction is lost in both 2F5 single mutants, F100BS and I100FS. 
 
MPER structural change upon 2F5 Fab interaction 
We carried out a structural investigation of the WT 2F5 interaction with the MPER in 
dodecylphosphocholine (DPC) micelles using NMR spectroscopy. The fingerprint 2D 
15N-TROSY (transverse-relaxation optimized spectroscopy)-HSQC (heteronuclear single 
quantum coherence) spectrum of 15N-13C-2D-labeled MPER peptide in the presence of 
unlabeled 2F5 Fab fragments showed large chemical-shift changes in the backbone amide 
peaks from a number of MPER residues (Figure A.4a and Supplementary Figure 6). 
MPER residues ranging from Leu660 to Phe673 were affected by 2F5 binding, with the 
most marked changes occurring for residues Lys665, Trp666 and Ala667 (numbering 
according to the HIV str. HXB2 peptide). These findings indicated that conformational 
changes in MPER subsequent to 2F5 binding extended well beyond the core epitope to 
include the central hinge region of MPER and possibly Thr676. Conversely, residues C- 
terminal to Thr676 were less perturbed, suggesting that the conformation of the C- 
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Figure A.3. Mass spectra showing the loss of protection from deuterium exchange in 2F5 mutants. 
(a,b) The spectra for wild-type 2F5, 2F5 F100BS and 2F5 I100FS are shown for peptides from 
CDRH3 (a) and CRDL2 (b) after 10 min in deuterated buffer. For each protein, spectra were 
obtained for undeuterated 2F5, 2F5 alone, 2F5 in the presence of MPER in solution (+ MPER 
only) and 2F5 in the presence of liposomes containing embedded MPER (+ MPER in lipid). The 
data shown in a for WT 2F5 are the same as the data shown in Figure A.2c. The bimodal, 
multiple-population phenomenon seen for WT 2F5 with MPER in solution were also observed at 
the other exchange time points (Figure A.2b). 
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 terminal helix of MPER remained largely unchanged (35). Secondary structures predicted 
from the 13C chemical-shift values of MPER bound to 2F5 implied that there were 
marked conformational changes to the N-terminal region (Figure A.4b). The N-terminal 
residues LLELD adopted an extended conformation when in contact with the antibody, 
and the helical conformation of the MPER N-terminal helix, including the core epitope, 
and of residues C-terminal to the 2F5-binding pocket had been disrupted.  
 
To map the 2F5-bound MPER residues that are in close contact with the Fab, we acquired 
cross-saturation transfer 15N-TROSY-HSQC spectra (36) using the same sample. The 
aliphatic-proton spectral region from the 2F5 Fab was irradiated and the saturation 
signals transferred to the amide peaks of the MPER through intermolecular NOE when 
residues of the MPER were close in space to the 2F5 surface. In this way, MPER residues 
nearby the 2F5 Fab were identified. Figure A.4c shows the relative amount of signal 
reduction as a result of cross-saturation transferred from the 2F5 to the Fab-bound MPER 
residues. The most affected residues were in the core epitope region, but close contacts 
between the antibody and MPER extended C-terminally to include the MPER central 
hinge region. The region of intermolecular contact appeared to be between Glu662 and 
Phe673, a region that was similar in scope to that identified by the chemical-shift-
perturbance data. The overall saturation levels were comparable to those of 4E10-bound 
MPER, but they were less than half those of Z13e1-bound MPER (35), suggesting that 
2F5 binding is similar to 4E10 binding and involves a small but deep epitope-binding 
pocket with a larger paratope contact area. By contrast, Z13e1 ligation is a rigid type of 
binding involving many MPER residues. In addition, cross-saturation data showed that   
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Figure A.4. NMR characterization of the MPER segment from HIV str. HXB2 on 2F5 Fab 
ligation. (a) MPER backbone amide chemical-shift changes on binding to 2F5 Fab. The chemical-
shift values of amide 15N and 1H were normalized as (∆H2 + (∆N/5)2)1/2. (b) Secondary structures 
predicted from MPER chemical shifts by TALOS+. Red and light-blue bars indicate probabilities 
of helical and β-strand conformations, respectively, whereas gray bars represent unstructured 
states. (c) Signal reduction observed in 2D-labeled MPER backbone amide peaks as transferred 
from 1H-saturated 2F5 Fab to 2D-labeled MPER. 
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 the side chain amine groups of Trp670 and Trp672 were both in close contact with 2F5 
(see Supplementary Figure 6b). Although Trp666 in the ELDKWA epitope was expected 
to make closer contacts with 2F5, its peak was not observed, consistent with a rapid 
relaxation rate in the binding pocket. Overall, our data suggested that there were multiple 
contacts between 2F5 and MPER outside the ELDKWA core itself, including the region 
immediately flanking this core and up to the central hinge region (residues Phe673–
Asn674). 
 
MPER alanine scanning on binding of WT and mutant 2F5 
To determine whether broader contacts with MPER residues C-terminal to the 2F5 core 
epitope were mediated by CDRH3 apex residues, binding of WT 2F5, 2F5 I100FS and 
2F5 F100BS was compared through mutational-scanning analysis. Single-residue alanine 
substitutions of the MPER showed that the DKW sequence was essential for 2F5 binding 
to the MPER on the dioleoylphosphatidylcholine-dioleoylphosphatidylglycerol (DOPC-
DOPG) liposome (Figure A.5a), consistent with previous results carried out in solution 
(22, 37, 38). In contrast to binding of WT 2F5, the binding of 2F5 I100FS and 2F5 
F100BS was affected by residues in addition to those core DKW residues, extending C-
terminally as far as Trp678 (Figure A.5a,b). An A667D mutation considerably 
diminished 2F5 I100FS and 2F5 F100BS binding (to ~4–6% that of WT 2F5), as did 
alanine replacement of membrane-embedded Leu669, Trp670, Trp672, Phe673, Ile675 
and Trp678, and of surface-exposed Asn671, Asn674, Thr676 and Asn677. Independent 
peptide analyses using a full-length MPER segment as well as a synthetic, C-terminally 
truncated MPER demonstrated that although WT 2F5 binding to the MPER was 
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 unaffected by residues C-terminal to the MPER N-terminal helix, truncation of the 
MPER C-terminal helix diminished 2F5 I100FS and 2F5 F100BS binding as a result of a 
faster dissociation rate (Figure A.5c,d). The binding of 2F5 L100AS F100BS to the 
truncated MPER (Figure A.5d) was abrogated even at the tested antibody concentration 
of 100 µg ml−1, although binding to full length MPER was detectable. In summary, the 
results suggested that the membrane interaction of CDRH3 tip fostered transient contact 
of 2F5 CDRH3 with residues in the C-terminal helix of MPER during initial or 
intermediate binding states. 
 
The apex of the 2F5 CDRH3 loop mediates epitope extraction 
To test the effect of mutations at the tip of the CDRH3 loop on MPER reorientation and 
to find any correlation with neutralization potency, membrane immersion depths of spin-
labeled (R1) MPER reference residues L669R1 and W670R1 (35) were measured by 
EPR for 2F5 L100AS, 2F5 F100BS and 2F5 I100FS. As shown in Figure A.6a, we 
determined the immersion depth values in the absence and presence of 2F5 Fab. We 
found that WT 2F5 Fab lifted the deeply buried residue L669R1 from the acyl chain 
region of lipid (depth >8 Å) out of the membrane surface and into the aqueous phase 
(depth < –5 Å), whereas W670R1 was moved from the lipid acyl chain region into the 
head group region. In contrast to WT 2F5 Fab, 2F5 F100BS-induced immersion depth 
changes of L669R1 and W670R1 were attenuated at the head group and acyl chain 
regions, respectively (Figure A.6a). The extraction of L669R1 appeared to be unaffected 
by 2F5 L100AS and 2F5 I100FS, but slightly reduced immersion depth changes were 
observed  with  W670R1 on 2F5 L100AS and 2F5 I100FS binding, compared to the  
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Figure A.5. Influence of C-terminal MPER residues on 2F5 and 2F5 binding, as measured by 
surface plasmon resonance (SPR). (a,b) Each bar represents the apparent 2F5 I100FS (a) and 2F5 
F100BS (b) binding affinities in comparison with those of WT 2F5 for a series of alanine-
substituted MPER peptides versus WT MPER. For Ala667, an aspartate substitution was 
introduced. The amount of each variant MPER peptide bound to DOPC-DOPG liposome was 
normalized to that of WT MPER peptide. WT and mutant 2F5 forms were injected over the 
peptide-liposome complex. Apparent binding affinities of each antibody for the MPER variants 
and WT MPER were measured by response units taken on the dissociation time point at 3 min, 
following 3 min of association time, by SPR. (c,d) Binding of WT and mutant 2F5 to MPER 
peptides containing or lacking the C-terminal helical MPER region. Each antibody was injected 
over the peptide–liposome complex, and the binding affinities were measured. 
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 changes induced by WT 2F5. The results suggest that mutations at different positions of 
the DRH3 tip differentially affect the degree of reorientation of the N-terminal helix in 
the MPER. Of note, comparable changes in the EPR mobility spectra for L669R1 and 
W670R1 (see Supplementary Figure 7) indicated the presence of similar MPER 
conformations at the antibody-binding interface for the WT and three mutant 2F5 Fabs. 
 
To further test whether the attenuated extraction of residues in the N-terminal helix of 
MPER by the 2F5 variants affected antibody interaction with intact GP41 on native 
membranes, we carried out fluorescence-activated cell sorting (FACS) analysis of mAb 
binding to the HIV-1 GP160(ADA) transiently expressed on 293 T cells. As shown in 
Figure A.6b, 36% of cells stained with WT 2F5, whereas the binding of 2F5 mutants was 
reduced: 26% of cells stained for 2F5 L100AS, 20% for 2F5 I100FS, 13% for 2F5 F100BS 
and 3.9% for 2F5 L100AS F100BS. No detectable binding of 11F10 to GP41 was 
observed, even at the concentration of 0.2 mg ml−1, consistent with the result shown in 
the SPR analysis (Figure A.1b). These results suggested that the reorientation of 
membrane-embedded residues at the interface of the 2F5-binding pocket, mediated by 
CDRH3, was crucial both for binding affinity and, as previously shown (27), for 
neutralization potency. 
 
A model of 2F5 Fab binding to the MPER 
On the basis of these NMR, EPR, HX-MS and functional results, we modeled the full-
length MPER in complex with WT 2F5 Fab on a liposome surface. Details of the 
modeling are provided in the Online Methods. As shown in Figure A.7a, the N-terminal 
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 segment of the MPER has been lifted vertically out from the membrane, and contacts 
between the hydrophobic CDRH3 loop and MPER juxta-hinge residues probably 
contribute to complex stabilization. We propose that the CDRH3 loop acts like a scoop to 
extract the 2F5 core epitope residues into its binding pocket. As viewed from a 90° 
rotation of this MPER-2F5 Fab complex model, shown in Figure A.7b, extraction causes 
664DKW666 to fit into the deep binding pocket of 2F5, whereas 662EL663 and 669LW670 line 
the entrance and exit, respectively. The hydrophobic tip of the 2F5 CDRH3 loop is 
positioned in the membrane to be compatible with the HX-MS data. 
 
Notably, the 2F5 CDRH3 loop is rigidified by a cross-strand hydrogen bond network and 
the presence of three proline residues, and this rigidification facilitates extraction. 
Figure A.7c shows a comparison of crystallographically defined CDRH3 loops of the 
BNAbs 2F5, 4E10 and Z13e1.  The proline-containing, scoop-like structures of the 
CDRH3 loops of the extracting BNAbs, 2F5 and 4E10, are in contrast to the flat, paddle-
like CDRH3 structure of the non-extracting BNAb, Z13e1 (35). 
 
 
DISCUSSION 
A multistep process of 2F5 binding to lipid-embedded MPER 
2F5 binding to the MPER proceeds through several distinct steps. Given  the  weak  
interaction  of  2F5  with  lipid  membranes,  yielding  undetectable  alterations  by  the  
HX-MS experiments (see Supplementary Figure 5), we suggest that 2F5 initially interacts  
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Figure A.6. Changes in membrane immersion depth in MPER following 2F5 ligation, and the 
relationship to binding of the trimeric envelope protein. (a) WT and mutant 2F5 Fabs-induced 
changes in the membrane immersion depth of MPER R1 residues, assessed by EPR. Depth values 
between –5 Å and 0 Å and larger than 0 Å correspond to the lipid head group region and the acyl 
chain region, respectively. The precise values of residues exposed to the aqueous phase (depth <–
5 Å) could not be determined experimentally and are thus indicated by black arrows. (b) WT 2F5, 
mutant 2F5 and 11F10 binding to the HIV-1 strain, ADA envelope trimer expressed on 293 T 
cells. Histograms indicate relative % cell staining by each antibody after subtraction of 
background staining against mock-transfected cells (gray). Note the absence of cell staining by 
11F10 even at the concentration of 200 µg ml-1.  
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 with the solvent-exposed MPER residues Glu662, Leu663 and possibly Asp664, lifting 
up the MPER residues N-terminal to Asp664. As a result, the 2F5 CDRH3 loop comes 
into contact with the MPER at the peptide-lipid interface on the Trp672 side. The 
 
hydrophobic residues in the CDRH3 loop then insert deeper into the membrane to 
stabilize a β-sheet hairpin structure and, together with the proline- containing base of the 
loop, form a rigidified scoop. We suggest that this scoop lifts up the underside of the N-
terminal helical segment of the MPER. That action involves a concerted movement in 
which the CDRH3 loop sweeps across the N-terminal front of the MPER, contacting 
Asp664, Lys665 and Trp666, and extracts Lys665 and Trp666 from the membrane into 
the 2F5 binding pocket, resulting in a tight complex. The tip of the CDRH3 loop with 
Phe100B anchored into the membrane is crucial to stabilize the 2F5-MPER complex in 
this process. The single population of 2F5 CDRH3 and CDRL2 peptides that were 
protected from deuterium exchange in the presence of MPER embedded in liposome was 
probably an HX-MS correlate of this process. 2F5 F100BS and, to a lesser extent, 2F5 
L100AS and2F5 I100FS were less effective in excavating the buried core epitope residues, 
thereby resulting in partial extraction with prolonged extraction kinetics, as evidenced by 
slower on-rate constants (Figure A.1d). We propose that those 2F5 mutations prevent the 
CDRH3 regions from interacting strongly with the MPER in lipid, resulting in the much 
faster appearance of highly deuterated species in HX-MS (Figures A.2 and A.3). This 
incomplete extraction may explain the observation that 2F5 100FS and 2F5 F100BS were 
sensitive to alanine mutations in the central hinge and the first turn of the C-terminal 
helix of MPER (Figure A.5). Although there may be no contacts with these MPER  
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Figure A.7. MPER in complex with 2F5 Fab on viral membrane surface. (a) Docking model 
showing 2F5 lifting up the N-terminal segment of the MPER. The MPER backbone ribbon is 
colored in red. 2F5 Fab is represented by a Van der Waals surface with hydrophobic patches in 
green. The membrane is colored gray (solvent-lipid head group interface, light gray; phosphate-
containing plane, medium gray; lipid head group–aliphatic-chain interface, dark gray). (b) 
Alternative view of the MPER–2F5 complex docking model, showing the scoop-like action of the 
2F5 CDRH3 (light blue). Key 2F5 epitope residues (664DKW666), red; residues critical for initial 
binding (662EL663) and used for EPR immersion depth probes (669LW670), green; 2F5 CDRL2 loop 
region that is closely coupled to the CDRH3 loop, orange. (c) Comparison of X-ray 
crystallographic structures of the CDRH3 loops of the neutralizing antibodies 2F5 (PDB 1TJI)19, 
4E10 (PDB 1TZG)10 and Z13e1 (PDB 3FNO)54. Hydrophobic residues, green (including proline 
side chains); hydrogen bonds, dotted red lines. 
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 residues in the final 2F5–MPER complex, during the intermediate stage of extraction, 
structural changes linked to the MPER alanine mutants and/or loss of direct side chain 
contacts may interfere with the extraction process mediated by these 2F5 CDRH3 
mutants. 
 
Functional consequences of the 2F5 mutations cannot be explained by loss of 
‘nonspecific’ hydrophobic membrane interactions that are the single prerequisite for the 
subsequent MPER binding, as suggested previously (28). Instead, 2F5 extraction of 
epitope residues on the MPER segment requires, in our view, three key regions: an initial 
MPER-capturing paratope adjacent to the core binding pocket (imparting specificity); a 
semirigid kinematic CDRH3 loop with flexible joints that can interact simultaneously 
with residues C-terminal to the binding pocket and with lipid membrane in an interaction 
that is necessary to extract core epitopes shielded by lipid head group or acyl chains 
(offering hydrophobic interaction energetics for lifting the MPER); and a tight paratope 
binding pocket for stable complex formation with the fully exposed core epitope 
(yielding a high affinity interaction).  
 
A proline-based molecular switch: 2F5 CDRH3 extraction scoop 
From a survey of 516 antibody structures in the Protein Data Bank (PDB) database, only 
~5% (26 of 516) possess rigid and long (≥14 residues) CDRH3 loops, including 2% (10 
of 459) of  non-HIV-targeting mAbs compared with 28% (16 of 57) of HIV-targeting 
mAbs. The CDRH3 loop of 2F5 is remarkable in its length (22 residues) and function, as 
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 noted above. We propose that the energy gained from favorable interactions of the 
CDRH3 tip with the membrane and MPER N-terminal segment can be efficiently 
transmitted through the rigid segments of the CDRH3 loop to facilitate extraction. 
Notably, the 2F5 CDRH3 loop contains three proline residues, a distinctive feature 
among known natural antibody structures in the PDB (aside from the tyrosine-sulfated 
412D antibody to HIV-1 GP120 (39). In the case of 2F5, glycine residues N-terminal to 
two of the three prolines (Pro98 and Pro100J) may afford segmental flexibility in the 
structure around these maneuverable ‘joints’. We envision that the cis-trans isomerization 
of these proline residues can act like a molecular switch (40, 41) to mediate dynamic 
robotic movement of the largely rigid CDRH3 loop for extraction (Figure A.7b,c), 
locking it into a trans-proline state. The conformational change of the 2F5 CDRH3 loop 
on 2F5 binding to membrane-bound MPER, as observed by HX-MS, is consistent with 
this notion. Moreover, that transition may position the hydrophobic residues on one 
surface of the CDRH3 tip for membrane interaction in an energetically favorable manner 
(27) that can provide the energy source and trigger for this switching mechanism.  
 
Implication for immunogen design 
CDRH3 is the major determinant of antibody diversity and a key contributor to antigen 
affinity and specificity(42). The selection bias of 2F5 progenitor B cells for a long 
CDRH3 loop may be driven by the context in which the MPER antigen is presented, 
being largely sterically occluded at the base of the glycosylated GP160 ectodomain in 
proximity to viral membrane (43). A correlation between CDRH3 length and the nature 
of the antigen being recognized would set a precedent for such selection (44, 45). 
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 Although some amino acids in the putative 2F5 germline antibody participated in 
interactions with certain core epitope residues, the germline-like antibody most closely 
corresponding to 2F5 lacks binding to soluble GP140 (46, 47). Somatic hypermutation 
may have occurred during prolonged antigen exposure, facilitating the generation of a 
higher-affinity antibody capable of neutralizing HIV-1 (48). Crystal structures of other 
germline and affinity-matured antibodies have revealed structural plasticity of CDRH3, 
with an evolution of antibody affinity and specificity (49). Hence, the high-affinity 
antigen-binding site of 2F5 may have evolved into an optimized binding site through 
conformational adaptation of the CDRH3 loop in proximity to the membrane. It is likely 
that one or more hydrophobic residue in the CDRH3 loop, including proline, coevolved 
for the extraction process and, as a result, enhanced antibody binding affinity by 
extending the 2F5 progenitor’s binding-site contacts to buried residues. The weaker 
affinity of CDRH3 tip variants of 2F5 and the importance of additional contacts with the 
MPER C terminus for binding of these variants may be reminiscent of the evolving 2F5 
progenitor during maturation.  
 
A 2F5-like antibody with high affinity is achieved through conformational adaptation of 
the  long CDRH3 loop in a membrane environment through extensive contact with 
MPER residues  and membrane constituents. In turn, the geometry of MPER on the virus, 
along with the approach angle of the antibody relative to the viral surface, must be 
considered in immunogen design. Given the rarity of naturally elicited BNAbs to MPER 
in individuals infected with HIV-1 (50), focusing the immune response on the MPER 
probably requires epitope-specific immunogens to avoid the immunodominance of other 
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 regions in GP41 and GP120. That said, presentation of the buried core epitope alone in an 
immunogen scaffold cannot generate a BNAb that first recognizes the membrane-
exposed MPER elements before core extraction. Antigen-driven B cell selection of 
neutralizing antibody may thus require a successive, complementary immunization 
strategy.  
 
Antibodies as tools to modify membrane-embedded structures 
The multistep process beginning with the initial antibody encounter with surface-
embedded MPER, followed by extraction and final ligation, resulting in structural 
rearrangement of the target, is not unique to 2F5. How the 4E10 CDRH3 function differs 
from that of 2F5 will be of interest to determine. The distinction in size, shape and 
number of prolines in the 2F5 and 4E10 CDRH3 scoops implies that important 
differences will be found in the extraction processes of these BNAbs and in the 
immunogens needed for their elicitation. Moreover, our findings have implications for 
exploiting antibodies to regulate key cellular-receptor functions through the induction of 
membrane-dependent reorganizations in macromolecular structure. Examples might 
include T cell receptors whose mechanosensor function is dependent on the physical 
force transmitted on ectodomain ligation (51), growth receptors such as the epidermal 
growth factor receptor (EGFR) family members being dependent on asymmetrical 
dimerization of the kinase domain (52), and plexins (receptors for semaphorins) inducing 
dimerization to control axonal guidance in the nervous system and cellular  migration  
more  generally (53). Development of antibodies that can either interdict or mimic ligand-
dependent events through membrane-directed structural rearrangements could create a 
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 new class of molecular robotic tools to regulate cellular processes (54). The HIV-1 GP41 
example shows that membrane-active antibodies have potent biological effects that can 
be studied in explicit molecular terms.  
 
METHODS 
Methods and any associated references are available in the online version of the paper at 
http://www.nature.com/nsmb/. 
Note: Supplementary information is available on the Nature Structural & Molecular  
Biology website. 
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